[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sarcoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sarcoma":784},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,139,0,25,[9,46,87,169,211,238,270,300,335,396,426,452,471,492,518,540,573,599,635,657,675,698,717,736,759],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053719",false,"NCT05253131","Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas","Phase 1\u002F2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor ZEN-3694 With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors","Inclusion Criteria:\n\nInclusion Criteria AGE: ≥ 18 years of age Weight: \\>30 kg Life expectancy of at least 12 weeks\n\nPart A and B (Phase 1): Patients with histologically confirmed soft tissue or bone sarcoma of the following subtypes:\n\n* MFH\u002F undifferentiated pleomorphic sarcoma\n* Unclassified sarcoma\n* Rhabdomyosarcoma\n* Malignant peripheral nerve sheath tumor (MPNST)\n* Osteosarcoma\n* Ewing or Ewing-like sarcoma\n* Synovial sarcoma\n* Desmoplastic small round blue cell tumor (DSRCT)\n\nPatients must have progressed or demonstrated disease that is refractory to standard therapies.\n\nPatients for whom no standard of care treatments exist are eligible.\n\nPart C (Phase 2): Patients with progressive, relapsed, unresectable or metastatic NF associated MPNST.\n\nMEASURABLE DISEASE:\n\nPatients must have evaluable or measurable disease (Phase 1) and measurable disease by RECISTv1.1 (Phase 2).\n\n* Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering on this study excluding chronic grade 1 toxicities and alopecia.\n* No limitation on the number of prior chemotherapy regimens that the patient may have received prior to study entry.\n* Myelosuppressive chemotherapy: The last dose of all myelosuppressive anticancer drugs must be at least 3 weeks (≥21 days) and 42 days if prior nitrosourea prior to study entry.\n* Immunotherapy: The last dose of immunotherapy (monoclonal antibody or vaccine) must be at least 4 weeks prior to study entry.\n* Biologic (anti-cancer agent): The last dose of all biologic agents for the treatment of the patient's cancer (such as retinoids or tyrosine kinase inhibitors) must be at least 7 days prior to study entry. Prior therapy with a MEK, Ras, or Raf inhibitor used for treatment of malignant sarcoma is not allowed. Prior therapy of MEK, Ras, or Raf inhibitor for other tumor such as plexiform neurofibroma or glioma is allowed.\n* Radiation therapy: The last dose of radiation to more than 25% of marrow containing bones (pelvis, spine, skull) must be at least 4 weeks prior to study\n* Radiation therapy: The last dose of radiation to more than 25% of marrow containing bones (pelvis, spine, skull) must be at least 4 weeks prior to study entry. The last dose of all other local palliative (limited port) radiation must be at least 2 weeks prior to study entry.\n* Stem Cell Transplantation. At least 2 months post-autologous stem cell transplant.\n* Growth Factors. The last dose of colony stimulating factors, such as filgrastim, sargramostim, and erythropoietin, must be at least 1 week prior to study entry, the last dose of long-acting colony stimulating factors, such as pegfilgrastim, must be at least 2 weeks prior to study entry.\n* Karnofsky performance level ≥ 50% (See Appendix II).\n* Patients who are unable to walk because of paralysis or motor weakness, but who are able to use a wheelchair will be considered ambulatory for the purpose of calculating the performance score.\n\nHemoglobin ≥9.0 g\u002FdL (transfusion permissible)\n\n* Peripheral absolute neutrophil count (ANC) of ≥1000\u002FµL\n* Platelet count ≥100,000\u002FµL (transfusion independent (no transfusion within at least 7 days prior to enrollment))\n* Total bilirubin must be ≤ 1.5 times the upper limit of normal (ULN)\n* SGOT (AST)\u002FSGPT (ALT) must be ≤ 3.0 times ULN unless liver metastases are present, in which case it must be ≤ 5x ULN\n\nRENAL FUNCTION:\n\nSerum creatinine ≤ 1.5 times ULN or measured reatinine clearance \\>50 mL\u002Fmin or calculated creatinine clearance \\> 50 mL\u002Fmin by the Cockcroft- Gault formula (Cockgraft and Gault 1976) or by the 24 hour urine collection for determination of creatinine clearance\n\n* Normal ejection fraction (ECHO or cardiac MRI) ≥53% (or the institutional normal; if a range is given then the upper value of the range will be used)\n* QTC or QTcF ≤ 450msec\n\nFertile men and women of childbearing potential must agree to use an effective method of birth control.\n\nFemale participants of childbearing potential must be willing to practice highly effective contraception as detailed below from the time of screening until 3 months after discontinuing the study.\n\nThey must not be breastfeeding and must have negative pregnancy test prior to start of dosing.\n\nFor a female participant to be considered as of not childbearing potential, she should fulfil one of the following:\n\nPost-menopausal women, defined as either women aged more than 50 years and have amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments, or, women under 50 years who have amenorrhea for at least 12 months following cessation of exogenous hormonal treatments, and have serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels in the postmenopausal range for the institution.\n\nor\n\n* Have documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy (but not tubal ligation)\n* Have medically confirmed, irreversible premature ovarian failure.\n\nHighly effective methods of contraception are:\n\n* Use of medroxyprogesterone acetate depot injection (Depo-proveraTM). (Please note: use of any other oral, injected, or implanted hormonal methods of contraception cannot be considered highly effective as it is currently unknown whether investigational agents may reduce their effectiveness)\n* Placement of a copper-banded intrauterine device (IUD) or intrauterine system (IUS)\n* Bilateral tubal ligation\n* Vasectomized partner\n\nBarrier methods include:\n\nOcclusive cap (e.g. diaphragm or cervical\u002Fvault caps) with spermicide\n\nMale participants should either be surgically sterile or willing to use an effective barrier method of contraception during the study and for 3 months following the last dose of drug therapy if sexually active with a female of childbearing potential. If not done, storage of sperm prior to receiving drug therapy will be advised to male participants with a desire to have children.\n\nMale subjects must agree to refrain from sperm donation during and until 90 days from drug therapy discontinuation.\n\nCNS DISEASE: Patients with central nervous system disease are eligible or enrollment if they have received prior radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression or stable disease at 4 weeks.\n\nExclusion Criteria:History of another primary malignancy except for\n\n* A malignancy treated with curative intent and with no known active disease ≥5 years prior to study entry\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n* Adequately treated carcinoma in situ without evidence of disease\n* Stable optic pathway glioma or low grade glioma not receiving active therapy\n\nHistory of leptomeningeal carcinomatosis.\n\nPatients receiving other anti-cancer agents are not eligible.\n\nPatients who cannot swallow whole pills.\n\nHistory of allogeneic organ transplantation.\n\nCurrent or prior use of immunosuppressive medications within 14 days prior to study entry. The following are exceptions to this criterion:\n\nintranasal, inhaled, topical steroids or local steroid injection (e.g., intra-articular injection)\n\nSystemic corticosteroids used at physiologic doses not to exceed 10mg\u002Fday of prednisone or its equivalent.\n\nSteroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).\n\nPatients should not receive immunizations with attenuated live vaccines within four weeks of study entry or during study period.\n\nAny recent major surgery within a minimum of 4 weeks prior to starting drug therapy. Placement of vascular access device, percutaneous tumor biopsy, or bone marrows are not considered major surgical procedures and no minimum time frame prior to starting study drug.\n\nPatients who have any known severe and\u002For uncontrolled medical therapy is required.\n\nconditions or other conditions that could affect their participation in the study such as:\n\n* Severely impaired lung function defined as spirometry and DLCO that is 50%of the normal predicted value corrected for hemoglobin and alveolar volume and\u002For O2 saturation that is 88% or less at rest on room air. For patients who do NOT have respiratory symptoms (e.g., dyspnea at rest, known requirement for supplemental oxygen), pulmonary function test is not required.\n* Cardiac conditions as follows:\n\n  * Uncontrolled hypertension (blood pressure ≥150\u002F95 mmHg despite medical therapy.\n  * Acute coronary syndrome within 6 months prior to starting drug therapy\n  * Uncontrolled angina despite medical therapy (Canadian Cardiovascular Society grade II-IV despite medical therapy\n  * Symptomatic heart failure NYHA Class II-IV prior or current cardiomyopathy or severe valvular disease\n  * Prior or current cardiomyopathy including but not limited to the following: Known hypertrophic cardiomyopathy; Known arrhythmogenic right ventricular cardiomyopathy; or Previous moderate or severe impairment of left ventricular systolic function (LVEF \\\u003C45% on echocardiography or equivalent of MUGA) even if full recovery has occurred\n  * Atrial fibrillation with a ventricular rate of \\>100 beats per minute on ECG at rest\n* Uncontrolled infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* Active primary immunodeficiency\n* Pre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi Syndrome, or renal tubular acidosis.\n* Current gastrointestinal conditions such as refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of small bowel, symptomatic inflammatory bowel disease, or ulcerative colitis, or partial or complete bowel obstruction.\n* Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease (colitis, Crohn's), celiac disease, systemic lupus erythematosus, Wegener syndrome, myasthenia gravis, Graves' disease, rheumatoid arthritis, uveitis.\n\nThe following exceptions are:\n\n* Patients with vitiligo or alopecia\n* Patients with hypothyroidism (e.g., following Hashimoto's syndrome) stable on hormone replacement\n* Psoriasis that does not require systemic therapy\n* Patients with celiac disease that is controlled by diet alone\n\n  • Ophthalmological conditions as follows:\n* Current or past history of retinal vein occlusion\n* Known intraocular pressure (IOP)\\>21 mmHg (or ULN adjusted by age) or uncontrolled glaucoma.\n* Subjects with ophthalmological findings secondary to long standing optic pathway glioma (such as visual loss, optic nerve pallor, or strabismus) or long standing orbito-temporal PN (such as vision loss, strabismus) will not be considered a significant abnormality for purposes of this study.\n\nAny Supplementation with vitamin E.\n\nHypersensitivity to investigational products, or drugs with similar chemical structures to investigational products.\n\nPatients unwilling or unable to comply with the protocol.\n\nWhile not an exclusion criterion, unless clinically indicated, patients should avoid taking other additional non-study medications that may interfere with the study medications. In particular, participants should avoid medications that are known to either induce or inhibit the hepatic activity of CYP1A2, CYP2C19, and CYP3A4.","ALL","18 Years","99 Years",{"count":20,"type":21},41,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","A multi-institutional open-label phase 1\u002F2 trial of selumetinib in combination with ZEN-3694 and durvalumab in refractory\u002Funresectable sarcomas including MPNST. The phase 1 portion will be separated in two parts and will be open to all patients with refractory\u002Frelapsed sarcomas. The phase 2 portion will be for patients with refractory\u002Funresectable NF1-associated MPNST.",[27,28,29],"MPNST","NF1","Sarcoma",[27,31,28,32],"Neurofibromatosis 1","sarcoma","NOT_YET_RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":21},"2026-11-15",{"date":41,"type":21},"2032-11-15",{"name":43,"class":44},"University of Alabama at Birmingham","OTHER",1,{"id":47,"slug":4,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100597545","NCT07059884","Distance-Based Exercise to Preserve Function and Prevent Disability","DEFEND","Inclusion Criteria:\n\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must have histologically confirmed diagnosis of one of the following cancers: anus, bladder, breast, cervix, colon\u002Frectum, endometrium, esophagus, gallbladder, head\u002Fneck, kidney, liver, lung, ovary, pancreas, prostate, sarcoma, stomach\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must be initiating outpatient cytotoxic chemotherapy for curative intent of at least 10 weeks duration (with or without concurrent radiation, immunotherapy, or other targeted therapy). Patients must be enrolled and baseline measures collected on or before administration of their second cycle of cytotoxic therapy. Patients receiving outpatient cytotoxic chemotherapy for curative intent in the neoadjuvant or adjuvant setting are eligible. Patients receiving definitive chemoradiation for the tumors listed above, are also eligible. Regimens of immunotherapy or monoclonal antibodies ONLY are not eligible\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Age 18-64 years\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have metastatic cancer\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of severe cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity. Examples would include unstable angina, recent myocardial infarction, oxygen-dependent pulmonary disease, and osteoarthritis requiring imminent joint replacement. Moderate arthritis that does not preclude physical activity is not a reason for ineligibility\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot be pregnant, because this study involves remotely delivered exercise, and cannot be breast-feeding as patients must be receiving cytotoxic chemotherapy, during which breast-feeding is contraindicated\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of current alcohol, substance abuse, or dementia\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Engaged in full time gainful employment of at least 30 hours per week at the time of cancer diagnosis\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Currently no self-report of engagement in competitive sports (e.g. not training for running races, triathlons, etc.) AND no self-report of twice weekly progressive resistance exercise training for at least 3 consecutive months within the past year\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Self-reported ability to walk for 6 minutes (use of assistive devices will be allowed)\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Not participating in another weight loss, physical activity, or dietary intervention clinical trial\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Predicted 6MWT distance of 550 meters or less\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Concurrent enrollment in treatment or supportive care trials (other than those focused on weight loss or exercise) is allowed with the permission of the Alliance Executive Officer and both studies' study chairs\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Eligibility is restricted to individuals who can comprehend and read English given that participation in the study will require the ability to read intervention materials and work with a coach through telehealth sessions\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): The trial is unable to accommodate the needs of deaf or blind participants as the study relies on language and visualization of exercise through telehealth sessions\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Clinicians and research staff from enrolling sites who meet following criterion will be deemed eligible to participate as a clinical stakeholder:\n\n  \\* Providing clinical care for participating patients on this study\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Ability to speak and understand English\n\nExclusion Criteria:\n\n\\-",{"count":53,"type":21},104,[55],"NA","This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side effects can make it difficult to work, take care of family, and do other things the patient wants to do. Preliminary research shows that exercise can help prevent some of these side effects, but it can be more difficult to start an exercise program when a patient is receiving cancer treatment. The exercise program in this study is delivered through telehealth (TH) video calls. The TH sessions are delivered by trained staff that supervise resistance exercises. The trained staff also provide guidance to the patient on completing unsupervised aerobic sessions on their own. This may be a successful way to deliver an exercise program and make it easier for cancer patients to exercise in their own home during treatment.",[58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,29],"Localized Malignant Solid Neoplasm","Anal Cancer","Bladder (Urothelial, Transitional Cell) Cancer","Breast Cancer","Cervical Cancer","Colon Cancer","Endometrial Cancer","Esophageal Cancer","Gall Bladder Cancer","Gastric Cancer","Kidney Cancer","Liver Cancer","Lung Cancer","Head and Neck Cancer","Ovarian Cancer","Pancreatic Cancer","Prostate Cancer","Rectal Cancer","RECRUITING","2026-07-01",{"date":79,"type":37},"2026-07-02",{"date":81,"type":37},"2026-02-11",{"date":83,"type":21},"2027-08-31",{"name":85,"class":44},"Alliance for Clinical Trials in Oncology",18,{"id":88,"slug":4,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":93,"sex":16,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":98,"phases":4,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":162,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},"100464928","NCT05334069","Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","Blinded Reference Set for Multicancer Early Detection Blood Tests","Inclusion Criteria:\n\n* Participants with a cancer diagnosis: Documentation of disease:\n\n  * Histologic documentation: Histologically confirmed diagnosis of invasive cancer\n  * Stage: Stage I-IV per American Joint Committee on Cancer (AJCC) 7th edition, with the exception of patients with leukemia, lymphoma, and multiple myeloma\n\n    * For leukemia: Type (chronic lymphocytic leukemia \\[CLL\\], chronic myeloid leukemia \\[CML\\], acute lymphoblastic lymphoma \\[ALL\\], acute myeloid leukemia \\[AML\\])\n    * For lymphoma: Stage I-IV based on Ann Arbor staging\n    * For multiple myeloma: Stage I, II, III based on Revised International Staging System (RISS)\n  * One of the following tumor types:\n\n    * Colorectal\n    * Bladder\n    * Head and neck\n    * Hepatobiliary\n    * Lung\n    * Lymphoma\n    * Leukemia\n    * Ovary \\*\\*\\* For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment\n    * Pancreas \\*\\*\\* For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment\n    * Multiple myeloma\n    * Gastric, esophageal or gastroesophageal\n    * Breast\n    * Thyroid\n    * Kidney\n\n      * For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment\n    * Endometrium\n    * Prostate\n    * Melanoma\n\n      \\*\\*\\* For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment\n    * Sarcoma\n* Participants with a cancer diagnosis: No prior definitive systemic or local anti-cancer intervention\n* Participants with a cancer diagnosis: Age \\>= 40 and =\\\u003C 75\n* Participants with a cancer diagnosis: No known current pregnancy by self-report\n* Participants with a cancer diagnosis: No known or prior history of in situ or invasive malignancy (excluding in situ non-melanoma skin cancers) other than the current cancer diagnosis\n* Participants with a cancer diagnosis: Willingness to provide blood samples for research use\n* Participants with a cancer diagnosis: Absence of medical contraindications to a research blood draw volume of 60 mL\n* Participants with a cancer diagnosis: No history of organ transplantation\n* Participants with a cancer diagnosis: Ability to read and comprehend English or Spanish\n\n  \\* Eligibility is restricted to individuals who can comprehend and read English or Spanish given that participation in the study will require the ability to read and complete questionnaires that are available only in those two languages\n* Participants without a cancer diagnosis and without suspicion of cancer: Age \\>= 40 and =\\\u003C 75\n* Participants without a cancer diagnosis and without suspicion of cancer: No known current pregnancy by self-report\n* Participants without a cancer diagnosis and without suspicion of cancer: No known or prior history of in situ or invasive malignancy (excluding in situ non-melanoma skin cancers)\n* Participants without a cancer diagnosis and without suspicion of cancer: Willingness to provide blood samples for research use\n* Participants without a cancer diagnosis and without suspicion of cancer: Absence of medical contraindications to a research blood draw volume of 60 mL\n* Participants without a cancer diagnosis and without suspicion of cancer: No history of organ transplantation\n* Participants without a cancer diagnosis and without suspicion of cancer: Ability to read and comprehend English or Spanish\n\n  \\* Eligibility is restricted to individuals who can comprehend and read English or Spanish given that participation in the study will require the ability to read and complete questionnaires that are available only in those two languages\n* Participants with a high suspicion of cancer: High suspicion of ovarian cancer, pancreatic cancer, kidney cancer, or melanoma by clinical and\u002For radiological assessment, with plans for histologic or cytologic confirmation within 28 days after study blood draw\n\n  \\* Examples of highly suspicious cases include: elevated CA125 and abnormal transvaginal ultrasound, suspicious renal or pancreatic mass on imaging, suspicious cutaneous lesion concerning for melanoma\n* Participants with a high suspicion of cancer: Central review of radiology reports and\u002For clinical documentation conducted by study chairs\n* Participants with a high suspicion of cancer: Age \\>= 40 and =\\\u003C 75\n* Participants with a high suspicion of cancer: No known current pregnancy by self-report\n* Participants with a high suspicion of cancer: No known or prior history of in situ or invasive malignancy (excluding in situ non-melanoma skin cancers) other than the current cancer diagnosis\n* Participants with a high suspicion of cancer: Willingness to provide blood samples for research use\n* Participants with a high suspicion of cancer: Absence of medical contraindications to a research blood draw volume of 60 mL\n* Participants with a high suspicion of cancer: No history or organ transplantation\n* Participants with a high suspicion of cancer: Ability to read and comprehend English or Spanish \\* Eligibility is restricted to individuals who can comprehend and read English and Spanish given that participation in the study will require the ability to read and complete questionnaires that are available only in those two languages",true,"40 Years","75 Years",{"count":97,"type":21},2000,"OBSERVATIONAL","This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.",[101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,29,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161],"Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Ann Arbor Stage I Lymphoma","Ann Arbor Stage II Lymphoma","Ann Arbor Stage III Lymphoma","Ann Arbor Stage IV Lymphoma","Chronic Lymphocytic Leukemia","Chronic Myeloid Leukemia","Gastroesophageal Junction Adenocarcinoma","Head and Neck Carcinoma","Hematopoietic and Lymphoid Cell Neoplasm","Invasive Breast Carcinoma","Kidney Carcinoma","Malignant Hepatobiliary Neoplasm","Malignant Solid Neoplasm","Melanoma","Muscle-Invasive Bladder Carcinoma","RISS Stage I Plasma Cell Myeloma","RISS Stage II Plasma Cell Myeloma","RISS Stage III Plasma Cell Myeloma","Stage I Bladder Cancer AJCC v6 and v7","Stage I Breast Cancer AJCC v7","Stage I Colorectal Cancer AJCC v6 and v7","Stage I Esophageal Cancer AJCC V7","Stage I Gastric Cancer AJCC V7","Stage I Lung Cancer AJCC v7","Stage I Ovarian Cancer AJCC v6 and v7","Stage I Pancreatic Cancer AJCC v6 and v7","Stage I Prostate Cancer AJCC v7","Stage I Uterine Corpus Cancer AJCC v7","Stage II Bladder Cancer AJCC v6 and v7","Stage II Breast Cancer AJCC v6 and v7","Stage II Colorectal Cancer AJCC v7","Stage II Esophageal Cancer AJCC v7","Stage II Gastric Cancer AJCC v7","Stage II Lung Cancer AJCC v7","Stage II Ovarian Cancer AJCC v6 and v7","Stage II Pancreatic Cancer AJCC v6 and v7","Stage II Prostate Cancer AJCC v7","Stage II Uterine Corpus Cancer AJCC v7","Stage III Bladder Cancer AJCC v6 and v7","Stage III Breast Cancer AJCC v7","Stage III Colorectal Cancer AJCC v7","Stage III Esophageal Cancer AJCC v7","Stage III Gastric Cancer AJCC v7","Stage III Lung Cancer AJCC v7","Stage III Ovarian Cancer AJCC v6 and v7","Stage III Pancreatic Cancer AJCC v6 and v7","Stage III Prostate Cancer AJCC v7","Stage III Uterine Corpus Cancer AJCC v7","Stage IV Bladder Cancer AJCC v7","Stage IV Breast Cancer AJCC v6 and v7","Stage IV Colorectal Cancer AJCC v7","Stage IV Esophageal Cancer AJCC v7","Stage IV Gastric Cancer AJCC v7","Stage IV Lung Cancer AJCC v7","Stage IV Ovarian Cancer AJCC v6 and v7","Stage IV Pancreatic Cancer AJCC v6 and v7","Stage IV Prostate Cancer AJCC v7","Stage IV Uterine Corpus Cancer AJCC v7","Thyroid Gland Carcinoma",{"date":79,"type":37},{"date":164,"type":37},"2022-08-18",{"date":166,"type":21},"2027-02-28",{"name":85,"class":44},745,{"id":170,"slug":4,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":98,"phases":4,"briefSummary":177,"conditions":178,"keywords":193,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":45},"100644985","NCT07675967","Clonal Hematopoiesis Chemotherapy and Radiation Effects Study","CH CARE","Inclusion Criteria:\n\n* Participants to be included in this study include the following:\n* Adults age \\>18 years\n* Diagnosed with solid malignancy (breast, ovarian, lung, gastric, colorectal, esophageal, uterine, head and neck, or sarcoma cancers)\n* Have a pending plan to receive chemotherapy or radiation for their solid malignancy (cancer).\n* Has not received cytotoxic chemotherapy or radiation for their solid cancer diagnosis in the past.\n\nExclusion Criteria:\n\n* Individuals without plans for cytotoxic chemotherapy, radiation or PARP inhibitor exposure\n* Individuals who have received prior chemotherapy and or radiation for their current solid malignancy (cancer)\n* Individuals with any prior history of blood cancer (leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, including smoldering multiple myeloma). Persons with blood cancer precursors including clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of uncertain significance (CCUS), monoclonal B lymphocytosis (MBL), monoclonal gammopathy of uncertain significance (MGUS) are eligible for study participation.",{"count":176,"type":21},5000,"The goal of the Clonal Hematopoiesis Chemotherapy and Radiation Effects (CH CARE) Study is to understand how the presence or absence of clonal hematopoiesis (CH) influences outcomes in people receiving chemotherapy and radiation for solid cancers.\n\nThe study will collect biospecimens and clinical information. These data will be used to define clinical and molecular features that predict the presence of high-risk clonal hematopoiesis (CH) in patients exposed to cytotoxic anti-cancer therapy. Predictive features will be utilized to identify populations of cancer patients and survivors who are at the highest risk of developing therapy-related myeloid neoplasms (t-MNs).\n\nUltimately this study will result in the development of a novel novel risk prediction algorithm for t-MNs in patients with solid cancers and drive potential therapeutic approaches to intercept progression from CH to often fatal t-MNs.",[179,180,181,182,61,183,184,29,185,186,187,188,71,189,190,191,192],"Lung Cancer (Diagnosis)","Osteochondroma","Spitz Nevus","Solid Cancers","Gastric (Stomach) Cancer","Colorectal (Colon or Rectal) Cancer","Ovarian Adenocarcinoma","Uterine Adenocarcinoma","Endometrial Adenocarcinoma","Esophageal Adenocarcinoma","Therapy-Related Acute Myeloid Leukemia","Therapy-Related MDS","Clonal Hematopoiesis of Indeterminate Potential (CHIP)","Clonal Cytopenia of Undetermined Significance",[194,195,196,197,198,199,200,201],"Adult cancer survivors","Precursor Lesions","clonal hematopoiesis","chemotherapy","radiation","therapy-related myeloid neoplasms","CCUS","clonal hematopoiesis of indeterminate potential","2026-06-29",{"date":204,"type":37},"2026-06-30",{"date":206,"type":37},"2025-04-04",{"date":208,"type":21},"2035-03-31",{"name":210,"class":44},"Dana-Farber Cancer Institute",{"id":212,"slug":4,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":219,"briefSummary":220,"conditions":221,"keywords":223,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":230,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":237},"100603259","NCT07134192","Fluorescence-Guided Optimization of Sarcoma Margins","FOCUS","Inclusion Criteria:\n\n* Biopsy verified intermediate-to-high grade sarcoma of theextremity or trunk wall\n* Age\\>18 years old\n* Tumor operable\n* Curative intent at time of surgery\n* Consent of patient\n\nExclusion Criteria:\n\n* History of allergic reaction to iodine-containing pharmaceuticals\n* End-stage renal disease or eGFR \\\u003C15\n* Patient decision\n* Lack of capacity\n* Inoperability",{"count":218,"type":21},90,[55],"This is a Danish national multicenter prospective cohort study to evaluate if fluorescence-guided surgery (FGS) using indocyanine green (ICG) can reduce the rate of positive margins following sarcoma resection.",[222,29],"Soft Tissue Sarcoma of the Trunk and Extremities",[29,224,225,226,227,228,229],"ICG","Indocyanine green","Fluorescence Guided Surgery","FGS","STS","Soft Tissue Sarcoma",{"date":77,"type":37},{"date":232,"type":37},"2025-09-01",{"date":234,"type":21},"2028-03-01",{"name":236,"class":44},"University of Aarhus",2,{"id":239,"slug":4,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":22,"phases":246,"briefSummary":248,"conditions":249,"keywords":257,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":261,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":269},"100575356","NCT06771219","SLV-154 Treatment of Metastatic Solid Tumors","A Phase 1 Dose-Escalation Study of SLV-154 in Subjects With Metastatic Solid Tumors","Inclusion Criteria:\n\n1. Men or women (as appropriate for cancer type) of age ≥18 years.\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n3. Histologically or cytologically confirmed diagnosis of solid tumor as documented in medical records with the primary history comprising one of the following:\n\n   1. SCCHN\n   2. NSCLC\n   3. SCLC\n   4. Breast cancer\n   5. Cervical cancer\n   6. Endometrial cancer\n   7. Ovarian cancer\n   8. Urothelial cancer\n   9. Sarcoma\n   10. Thyroid cancer\n4. Presence of metastatic disease that has progressed during or following previous treatment.\n5. Presence of radiographically measurable disease.\n6. Prior receipt of commercially available therapies that are indicated for the subject's cancer and have demonstrated survival benefit for that indication.\n7. Availability of tumor tissue from a fresh tumor biopsy obtained by a core needle, excisional, or incisional biopsy; or punch biopsy (for cutaneous disease); or archival tumor sample from a previous biopsy.\n8. Availability of computed tomography (CT) or magnetic resonance imaging (MRI) of chest, abdomen, and pelvis, and\u002For fluorodeoxyglucose (FDG) positron emission tomography (PET)\u002FCT (if appropriate for tumor type) (with PET from base of the skull to mid-thigh, if performed) within 35 days before study drug administration.\n9. Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, or investigational therapy) for the treatment of cancer ≥1 week before the start of study drug administration.\n10. Adequate hematological profile.\n11. Adequate coagulation profile.\n12. Adequate hepatic profile.\n13. Adequate renal function.\n14. Negative viral serology or adequate therapy for human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) infection.\n15. For female subjects of childbearing potential, a negative serum pregnancy test.\n16. For female subjects of childbearing potential, willingness to use a protocol-recommended method of contraception from the start of the screening period until ≥6 months after the final dose of study therapy.\n17. For male subjects who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol-recommended method of contraception from the start of study therapy until ≥6 months after the final dose of study therapy and to refrain from sperm donation from the start of study therapy until ≥12 months after administration of the final dose of study therapy.\n18. Willingness and ability of the subject to comply with scheduled visits, the drug administration plan, protocol-specified laboratory tests, other study procedures (including required tumor biopsy\u002Faspirations and\u002For radiographic studies), and study restrictions.\n19. Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.\n\nExclusion Criteria:\n\n1. Malignancy involving the central nervous system unless brain metastases have been previously treated with radiotherapy, have been stable for ≥4 weeks, and do not require corticosteroids.\n2. Presence of another cancer with disease manifestations or therapy that could adversely affect subject safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.\n3. Uncontrolled ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infection) at the time of start of study therapy.\n4. Significant cardiovascular event or comorbidity.\n5. Significant screening ECG abnormalities.\n6. Pregnancy or breastfeeding.\n7. Major surgery within 4 weeks before the start of study therapy.\n8. Use of a strong inhibitor or inducer of CYP3A4 or CYP1A2.\n9. Use of a drug known to prolong the QT interval within 7 days prior to the start of study drug administration.\n10. Concurrent participation in another therapeutic or imaging clinical trial.\n11. Other conditions likely to interfere with a subject's ability to participate in the study.",{"count":245,"type":21},70,[247],"PHASE1","This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with metastatic solid tumors.",[250,251,252,253,254,64,72,255,29,256],"Squamous Cell Cancer of Head and Neck (SCCHN)","NSCLC","SCLC","Cervical Cancer Metastatic","Breast Cancer Metastatic","Urothelial Cancer","Thyroid Cancer",[258,259,260],"metastatic solid tumors","metastatic cancer","solid tumor",{"date":204,"type":37},{"date":263,"type":37},"2025-05-14",{"date":265,"type":21},"2027-04",{"name":267,"class":268},"Solve Therapeutics","INDUSTRY",10,{"id":271,"slug":4,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":16,"minAge":276,"maxAge":277,"enrollmentInfo":278,"targetDuration":4,"studyType":22,"phases":280,"briefSummary":281,"conditions":282,"keywords":286,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":45},"100239104","NCT02390752","Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...","Phase I Trial of TURALIO (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCT)","* INCLUSION CRITERIA:\n* Diagnosis:\n\n  * Individuals must have recurrent or refractory solid tumors or acute leukemia (limited to AML or ALL) or have been intolerant of prior therapies, confirmed by the Laboratory of Pathology, NCI, e.g., solid tumors including rhabdomyosarcoma, Ewing sarcoma, soft tissue sarcomas. These may include primary neoplasms of the central nervous system, such as high-grade (WHO grade III-IV) glioma. Individuals with diffuse intrinsic pontine glioma (DIPG) or optic pathway glioma are exempt from histologic verification. For DIPG typical MRI findings must be present which include hypo- or isointense on T1-weighted imaging, hyperintense on FLAIR or T2-weighted imaging, epicenter in the pons in the face of a typical clinical presentation. Optic pathway gliomas are located in the optic pathway and are typically hypo- or iso-intense on T1 and hyperintense on T2-weighted images.\n  * In addition, individuals with NF1 and with malignant peripheral nerve sheath tumor (MPNST).\n\n    * Individuals must have relapsed after or be refractory to effective standard therapies. There are no limits on number of prior therapeutic regimens.\n* Disease status: Individuals with refractory solid tumors including patients with NF1 and MPNST must have evaluable disease, patients with leukemia must have measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease detected by flow cytometry.\n* Age \\>= 3 and \\\u003C= 35 years of age (must have BSA \\>= 0.55 m\\^2):\n* Ability of subject or Legally Authorized Representative \\[LAR\\] (the parent\u002Fguardian if subject is a minor) to understand and the willingness to sign a written informed consent document.\n* Individuals must be able to swallow capsules.\n* Performance Status: Karnofsky \\>= 50% for patients \\> 16 years of age and Lansky \\>= 50% for patients \\\u003C= 16 years of age. Individuals who are wheelchair bound because of paralysis will be considered \"ambulatory\" when they are up in their wheelchair. Individuals have to be able to travel to the NIH for evaluations.\n* Prior therapy:\n\nIndividuals must have fully recovered (to Grade 1) from the acute toxic effects of all prior anti-cancer therapy.\n\n* Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea).\n* Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair.\n* Immunotherapy: At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines.\n* Monoclonal antibodies: At least 3 half-lives of the antibody after the last dose of a monoclonal antibody.\n* XRT: At least 7 days after local palliative XRT (small port); At least 150 days must have elapsed if prior TBI or if \\>= 50% radiation of pelvis; \\>= 14 days from whole brain radiation, craniospinal radiation, or targeted radiation to CNS tumors. At least 42 days must have elapsed if other substantial BM radiation.\n* HSCT: \\>= 56 days from stem cell transplant with no evidence of active graft vs. host disease; must be off immunosuppressive therapy for at least 4 weeks and have no active graft-versus-host disease (GVHD) at the time of entry onto this trial.\n* Surgery: \\>= 14 days from surgery\n* Others: \\>= 7 days from last dose of short active hematopoietic growth factors, i.e. filgrastim, \\>= 14 days for long-acting, i.e. pegfilgrastim.\n* Steroids: Individuals with CNS tumors who are managed with steroids are eligible if they have no worsening neurologic deficits and are on a stable or decreasing dose of corticosteroids for greater than or equal to 7 days prior to registration. Individuals with leukemia receiving corticosteroids or hydroxyurea are eligible provided that the corticosteroids are not being used to manage GVHD and there has been no increase in corticosteroid of hydroxyurea dose for 7 days prior to starting TURALIO(R).\n\n  -Individual must have adequate hematologic, hepatic, and renal function, defined by:\n* Absolute neutrophil count \\>= 1.5 x 10\\^9\u002FL\n* Hemoglobin \\> 10 g\u002FdL\n* Platelet count \\>= 100 x 10\\^9\u002FL\n* AST and ALT \\\u003C= upper limit of normal (ULN)\n* TBil and DBil \\\u003C= ULN with an exception of patients with confirmed Gilbert's syndrome. For patients with confirmed Gilberts syndrome, the TBil should be \\\u003C= 1.5 x ULN\n* Serum creatinine \\\u003C= 1.5 x ULN\n* Exceptions:\n\n  * Cytopenias due to underlying disease (i.e. potentially reversible with anti-neoplastic therapy); A subject will not be excluded because of cytopenia due to disease, based on the results of bone marrow studies.\n  * Known active or chronic human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection, or positive hepatitis B (Hep B) surface antigen. Prior hepatitis infection that has been treated with highly effective therapy with no evidence of residual infection and with normal liver function (ALT, AST, total and direct bilirubin \\\u003C= ULN) is allowed.\n  * Hepatobiliary diseases including biliary tract diseases, autoimmune hepatitis, inflammation, fibrosis, cirrhosis of liver caused by viral, alcohol, or genetic reasons. Gilbert's disease is allowed if TBil is \\\u003C= 1.5 x ULN.\n\n    * Cardiac ejection fraction \\>= 50%, and QTcF \\\u003C 450 ms (male) or \\\u003C470 ms (female) on ECG at Baseline. (Fridericia's Formula: QTcF = (QT)\u002FRR0.33)\n    * Contraception: Women of child-bearing potential must agree to use an effective method of birth control during treatment and for 1 month after receiving their last dose of study drug. Fertile men must also agree to use an acceptable method of birth control while on study drug and for at least one month after last dose.\n\nEXCLUSION CRITERIA:\n\n* Individuals who are pregnant or breast feeding or who become pregnant while enrolled on this trial will be excluded from participation, due to the unknown effects of TURALIO(R) on a growing fetus or newborn child.\n* Ongoing treatment with any other cancer therapy or investigational agent, with the exception of IT chemotherapy for leukemia, when indicated.\n* Individuals who require therapy with warfarin.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Active untreated infection.\n* Known active hepatitis A, B, C or HIV infection, chronic Hepatitis B or C, or HIV infection or inactive Hepatitis B carrier.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to TURALIO(R) or other agents used in study.\n* Individuals with PT and\u002For INR higher than or equal to 1.5 times upper limit of normal, unless patients have lupus anticoagulant in which case they are eligible if cleared by hematology.\n* Drugs that strongly inhibit or potentiate CYP3A4, which includes CYP3A4 inducer, UGT inhibitors and acid reducing agents and avoid concomitant use of PPIs:\n\n  * Individuals who have received these drugs within 14 days or within 5 half-lives of the drug (whichever is longer) prior to study initiation will be excluded.","3 Years","35 Years",{"count":279,"type":21},54,[247],"Background:\n\n\\- Some people with cancer have solid tumors. Others have refractory leukemia. This may not go away after treatment. Researchers want to see if a drug called TURALIO(R) can shrink tumors or stop them from growing.\n\nObjectives:\n\n\\- To find the highest safe dose and side effects of TURALIO(R). To see if it helps treat certain types of cancer.\n\nEligibility:\n\n\\- People ages 3-35 with a solid tumor or leukemia that has returned or not responded to cancer therapies.\n\nDesign:\n\n* Individuals will be screened with:\n* Medical history\n* Physical exam\n* Blood and urine tests\n* Heart tests\n* Scans or other tests of the tumor\n* Individuals will take TURALIO(R) as a capsule once daily for a 28-day cycle. They can do this for up to 2 years.\n* During the study, participants will have many tests and procedures. They include repeats of the screening tests. Individuals will keep a diary of symptoms.\n* Individuals with solid tumors will have scans or x-rays.\n* Individuals with leukemia will have blood tests. They may have a bone marrow sample taken.\n* Some individuals may have a biopsy.\n* When finished taking TURALIO(R), individuals will have follow-up visits. They will repeat the screening tests and note side effects.",[283,284,285,29],"Neurofibroma, Plexiform","Precursor Cell Lymphoblastic Leukemia-Lymphoma","Leukemia, Promyelocytic, Acute",[287,288,289,290],"Maximum Tolerated Dose","Dose Escalation","Acute Lymphocytic Leukemia","Acute Myelogenous Leukemia","2026-06-27",{"date":204,"type":37},{"date":294,"type":37},"2015-04-29",{"date":296,"type":21},"2028-12-31",{"name":298,"class":299},"National Cancer Institute (NCI)","NIH",{"id":301,"slug":4,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":307,"enrollmentInfo":308,"targetDuration":4,"studyType":98,"phases":4,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":334},"100602476","NCT07124000","DESTINY-PANTUMOUR04","Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study","DP-04","Inclusion Criteria:\n\n1. Adults aged ≥18 years\n2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the Investigator (see Exclusion Criterion 1 for excluded solid tumors);\n3. A clinician decision has been made for treatment with T-DXd in accordance with the FDA label;\n4. HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent;\n5. Patients who are willing and able to provide a signed and dated informed consent.\n\nExclusion Criteria:\n\n1. Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies;\n2. Prior T-DXd therapy;\n3. Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd.\n4. Patient is participating in a clinical trial at time of enrolment","130 Years",{"count":309,"type":21},100,"This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US",[312,59,313,62,64,65,66,314,71,69,116,315,316,317,72,73,74,318,319,29,320,321,322,256,323,324,325],"Adenocarcinoma (NOS)","Bladder Cancer","Gastrointestinal Stromal Tumour","Mouth Cancer","Nasopharangeal Cancer","Neuroendocrine, Gastrointestinal Cancer","Renal Cell Carcinoma","Salivary Gland Cancer","Small Cell Lung Cancer","Testicular Cancer","Throat Cancer","Urethral Cancer","Vaginal Cancer","Vulvar Cancer","2026-06-26",{"date":202,"type":37},{"date":329,"type":37},"2025-09-18",{"date":331,"type":21},"2028-03-30",{"name":333,"class":268},"AstraZeneca",17,{"id":336,"slug":4,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":93,"sex":16,"minAge":341,"maxAge":342,"enrollmentInfo":343,"targetDuration":345,"studyType":98,"phases":4,"briefSummary":346,"conditions":347,"keywords":377,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":395},"100210159","NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals","19 Years","110 Years",{"count":344,"type":21},999999,"80 Years","The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[73,256,70,65,348,63,75,349,59,350,351,352,67,69,353,354,355,356,313,68,357,74,321,358,323,359,360,361,362,363,364,365,366,319,367,368,369,370,61,371,116,29,372,373,72,64,324,374,375,376],"Thymus Cancer","Gastrointestinal Stromal Tumors","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Penile Cancer","Ureter Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Lip Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Skin Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Mesothelioma","Leukemia","Unknown Primary Tumor","Multiple Myeloma","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[73,256,378,379,380,381,382,383,384,385,61,386,375,376],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Thyroid Nodule","Lung Tumor","Neuroendocrine tumor","2026-06-25",{"date":202,"type":37},{"date":390,"type":37},"2013-11-01",{"date":392,"type":21},"2099-12",{"name":394,"class":44},"University of Nebraska",42,{"id":397,"slug":4,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":93,"sex":16,"minAge":401,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":98,"phases":4,"briefSummary":404,"conditions":405,"keywords":410,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":4,"leadSponsor":424,"locationsCount":425},"100141241","NCT01109394","Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies","* SUBJECT INCLUSION CRITERIA:\n\nPediatric or adult subjects with one of the following:\n\n* Diagnosis of any tumor, malignancy, pre-malignant disorder, or suspected premalignant familial syndromes, regardless, of patient age;\n* Biological relatives of any patient with a tumor, malignancy, pre-malignant disorder, or suspected familial pre-malignant syndrome, regardless of patient age or the diagnosis of an adult malignancy or pre-malignant disorder;\n* Healthy Volunteer without history of malignancy nor a family member currently being treated for cancer who are undergoing surgery, treatment or during well visits;\n* Biospecimens can be collected with minimal additional risk to the subject during sampling or procedures required for routine patient care.\n* Human samples, specimens and data collected on IRB approved protocols that are now closed\n* Ability of subject, Legally Authorized Representative (LAR), or parent\u002Flegal guardian of children \\\u003C=18 to understand and be willing to sign an IRB-approved informed consent document that permits the use of the tumor and other samples for genomic-based molecular characterization projects.\n\nInclusion Criteria for Social and Behavioral Outcome Interviews:\n\n* Parent\u002Fcaregiver of a participating pediatric or adult patient who is being treated for, or who has previously been treated for any form of pediatric cancer.\n* Must be able to give consent and sign the informed consent document.\n* Able to understand the English language.\n\nEXCLUSION CRITERIA:\n\nNone","4 Weeks",{"count":403,"type":21},6035,"Background:\n\n\\- Laboratory investigators who are studying common childhood cancers are interested in developing a tissue repository to collect and store blood, serum, tissue, urine, or tumors of children who have cancer or adults who have common childhood cancers. To develop this repository, additional samples will be collected from children and adults who have been diagnosed with common childhood cancers such as leukemia and tumors of the central nervous system.\n\nObjectives:\n\n\\- To collect and store blood, serum, tissue, urine, or tumor samples of children who have cancer or adults who have common childhood cancers.\n\nEligibility:\n\n* Individuals who have been diagnosed with a common childhood cancer (e.g., leukemia) regardless of patient age.\n* Children, adolescents, and adults who have been diagnosed with a type of cancer more commonly found in adults.\n\nDesign:\n\n* Extra blood, serum (the liquid part of blood), tissue, urine, or tumor samples will be collected from participants at a time when sampling is required for medical care or as part of a research study.\n* No additional procedures will be performed for the sole purpose of obtaining additional tumor tissue, aside from what is required for clinical care.",[29,406,407,408,409],"Endocrine Tumors","Neuroblastoma","Retinoblastoma","Renal Cancer",[411,412,413,414,415,416,417,418,29,68,407],"Genomics","Proteomics","Tissue Repository","Omics","Cell Lines","Natural History","Pediatric Cancer","Solid Tumor","2026-06-23",{"date":421,"type":37},"2026-06-24",{"date":423,"type":37},"2010-04-21",{"name":298,"class":299},5,{"id":427,"slug":4,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":11,"sex":16,"minAge":432,"maxAge":95,"enrollmentInfo":433,"targetDuration":4,"studyType":22,"phases":435,"briefSummary":436,"conditions":437,"keywords":440,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":447,"completionDateStruct":448,"leadSponsor":450,"locationsCount":45},"100395755","NCT04433221","Combination Immunotherapy Targeting Sarcomas","Safety and Efficacy Evaluation of a Combination Immunotherapy Targeting Sarcomas","Inclusion Criteria:\n\n1. Stage Ⅲ，Ⅳ sarcoma patients or recurrent sarcoma patients;\n2. Age: ≥ 6 months and ≤80 years of age at the time of enrollment;\n3. At least 2 weeks since the last standard chemotherapy or radiotherapy and immunosuppressive therapy such as steroid hormone before enrollment;\n4. Side effects of chemotherapy have been well managed;\n5. Confirmed malignant cell expression of CART target antigens by IHC or flow\n6. Karnofsky \u002Fjansky score of 50% or greater;\n7. Expected survival \\> 8 weeks;\n8. ANC≥ 1×10\\^6\u002FL，PLT ≥ 1×10\\^8\u002FL;\n9. Pulse oximetry of≥90% on room air；\n10. Adequate hepatic function, defined as aspartate aminotransferase(AST)\\\u003C 5 times upper limit of normal(ULN),serum bilirubin \\\u003C 3 times ULN;\n11. Adequate renal function, defined as serum creatinine less than 2 times ULN, if serum creatinine more than 1.5 times ULN, creatinine clearance rate test is needed;\n12. Patients must have sufficient autologous CART cells at does greater than 0.5x10\\^6 cells\u002Fkg body weight;\n13. Sign an informed consent and assent.\n\nExclusion Criteria:\n\n1. The disease is progressing rapidly;\n2. The patient is receiving therapy of other new drugs and under evaluation;\n3. Evidence of tumor potentially causing airway obstruction;\n4. Epilepsy history or other CNS diseases;\n5. Patients who need immunosuppressive drugs;\n6. History of long QT syndrome or severe heart diseases;\n7. Uncontrolled active infection;\n8. Active hepatitis B virus, hepatitis C virus or HIV infection;\n9. Receiving systemic corticosteroid 2 weeks before enrollment except for inhaled steroids;\n10. Previous treatment with any gene therapy;\n11. Creatinine\\>2.5mg\u002Fdl or ALT\u002FAST\\>3 times normal or bilirubin\\>2.0 mg\u002Fdl;\n12. Patients who have other uncontrolled diseases such as obstruction of lung function would preclude participation as outlined;\n13. Pregnant or lactating women;\n14. Patients previously experienced toxicity from cyclophosphamide and doxorubicin;\n15. Patients who have CNS sarcoma;\n16. In condition that may bring risks to subjects or interference to clinical trials.","1 Year",{"count":434,"type":21},20,[247,24],"The aim of this clinical trial is to assess the feasibility, safety and efficacy of a combination low dose chemotherapy and immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines multiple CAR T cells followed by sarcoma vaccines.",[29,438,439],"Osteoid Sarcoma","Ewing Sarcoma",[29,441,442,443,444],"Chemotherapy","Doxorubicin","CART","Vaccine","2026-06-18",{"date":419,"type":37},{"date":77,"type":21},{"date":449,"type":21},"2029-12-31",{"name":451,"class":44},"Shenzhen Geno-Immune Medical Institute",{"id":453,"slug":4,"hasResults":11,"nctId":454,"briefTitle":455,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":11,"sex":16,"minAge":432,"maxAge":95,"enrollmentInfo":457,"targetDuration":4,"studyType":22,"phases":458,"briefSummary":459,"conditions":460,"keywords":461,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":465,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":45},"100313156","NCT03356782","Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas","Inclusion Criteria:\n\n1. Stage Ⅲ，Ⅳ sarcoma patients or recurrent sarcoma patients;\n2. Age: ≥ 18 and ≤65 years of age at the time of enrollment;\n3. At least 4 weeks since any chemotherapy or radiotherapy and at least 1 week since immunosuppressive therapy such as using steroid hormone before enrollment;\n4. Side effects of chemotherapy have been well managed;\n5. Malignant cells are target antigen positive(higher than ++) confirmed by IHC, quantitative PCR or sequencing;\n6. Karnofsky \u002Fjansky score of 50% or greater;\n7. Expected survival \\> 6 weeks;\n8. ANC≥ 1×10\\^6\u002FL，PLT ≥ 1×10\\^8\u002FL;\n9. Pulse oximetry of≥90% on room air；\n10. Adequate hepatic function,defined as aspartate aminotransferase(AST)\\\u003C 5 times upper limit of normal(ULN),serum bilirubin \\\u003C 3 times ULN;\n11. Adequate renal function,defined as serum creatinine less than 2 times ULN,if serum creatinine more than 1.5 times ULN,creatinine clearance rate test is needed;\n12. Patients must have autologous transduced T cells at levels greater than 15%;\n13. Sign an informed consent and assent.\n\nExclusion Criteria:\n\n1. The disease is progresseing rapidly;\n2. The patient is receiving therapy of other new drugs;\n3. Evidence of tumor potentially causing airway obstruction;\n4. Epilepsy history or other CNS diseases;\n5. Patients who need immunosuppressive drugs because of GVAD;\n6. History of long QT syndrome or severe heart diseases;\n7. Uncontrolled active infection;\n8. Active hepatitis B virus,hepatitis C virus and HIV infection;\n9. Receiving systemic corticosteroid 2 weeks before enrollment except for inhaled steroids;\n10. Previous treatment with any gene therapy;\n11. Creatinine\\>2.5mg\u002Fdl or ALT\u002FAST\\>3 times normal or bilirubin\\>2.0 mg\u002Fdl;\n12. Patients who have other uncontrolled diseases would preclude participation as outlined;\n13. Pregnant or lactating women;\n14. Patients previously experienced toxicity from cyclophosphamide;\n15. Patients who have CNS sarcoma;\n16. In condition that may bring risks to subjects or interference to clinical trials.",{"count":434,"type":21},[247,24],"The aim of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines CAR T cells and IgT cells to treat sarcoma.",[29,438,439],[443,462,463,464,32,260],"PD-1","PDL-1","CTLA-4",{"date":419,"type":37},{"date":467,"type":37},"2026-06-01",{"date":469,"type":21},"2030-12-31",{"name":451,"class":44},{"id":472,"slug":4,"hasResults":11,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":22,"phases":479,"briefSummary":480,"conditions":481,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":45},"100641916","NCT07650656","Fluorescence-Guided Surgical Resection for Reducing Unexpected Positive Margins in Patients With Sarcoma, SarcoSIGHT Trial","SarcoSIGHT: A Randomized-Control Trial of Fluorescence Guided Sarcoma Surgery Versus the Standard of Care","Inclusion Criteria:\n\n* Documented written informed consent of the participant\n* Histologically confirmed diagnosis of intermediate to high grade sarcoma\n* All ages\n* Amenable to surgical resection as a part of curative intent for the patient\n* Willingness to:\n\n  * Respond to surveys during the trial\n  * Permit medical record\u002F clinical laboratory result review\n\nExclusion Criteria:\n\n* Due for surgery with palliative intent\n* Recurrent tumors\n* Intracranial, retroperitoneal, and visceral anatomical locations\n* A woman of childbearing potential who is currently pregnant (as confirmed by urine pregnancy test)\n* A woman who are currently breastfeeding\n* Known allergies to ICG, iodine, iodine dyes or shellfish\n* Unable to provide written and informed consent\n* Patients with hyper-thyroidism or autonomic thyroid adenomas\n* Premature infants\u002Fneonates with exchange transfusion indication due to hyperbilirubinemia",{"count":478,"type":21},22,[24],"This phase II trial compares standard of care surgical resection to fluorescence-guided surgical resection using indocyanine green and fluorescence imaging for reducing unexpected positive margin rates in patients with sarcoma. Surgical margins are one of the criteria used in assessing the effectiveness of a given surgical procedure. They are the edges or border of the tissue removed in cancer surgery. A negative margin means that the resected tumor is surrounded by normal tissue, which implies there is no disease left in the patient. By contrast, a positive margin means that sarcoma cells are visible at the edge of the tumor. Positive margins may be classified as planned when they are expected pre-operatively due to the preservation of a critical structure, or unexpected when the pathologist reports the presence of tumor at the margin despite the surgeon having intended to remove it in its entirety. Fluorescence-guided surgery is an established surgical method that involves the administration of fluorescent dye (in this case, indocyanine green) into the tumor, which can then be visualized with a special camera during surgery to help surgeons identify tumor versus healthy tissue. Fluorescence-guided surgery may reduce the rate of unexpected positive margins in patients undergoing surgery for sarcoma.",[482,29],"High Grade Sarcoma","2026-06-17",{"date":485,"type":37},"2026-06-22",{"date":487,"type":21},"2027-05-15",{"date":489,"type":21},"2028-05-11",{"name":491,"class":44},"City of Hope Medical Center",{"id":493,"slug":4,"hasResults":11,"nctId":494,"briefTitle":495,"officialTitle":495,"acronym":496,"eligibilityCriteria":497,"healthyVolunteers":11,"sex":16,"minAge":498,"maxAge":499,"enrollmentInfo":500,"targetDuration":4,"studyType":22,"phases":502,"briefSummary":503,"conditions":504,"keywords":507,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":517},"100644347","NCT07662239","Bridging Adolescent and Young Adult Sarcoma Survivors With Personalized Oncology Exercise Service (AYA-ONE): A Pilot Intervention","AYA-ONE","Inclusion Criteria:\n\n* Diagnosed with a bone or soft tissue sarcoma\n* Age 15-39 at time of diagnosis\n* Age 15 and older at time of enrollment\n* Age 15-17 at time of enrollment, with assent from participant and consent from parent\u002Flegal guardian\n* Established patient of the DFCI Sarcoma Center or Jimmy Fund\n* Able to read and understand English (to complete required questionnaires and participate in training\u002Fcoaching)\n* Individuals who are not yet adults (teenagers) if they assent and their parents\u002Flegal guardians' consent to participation.\n\nExclusion Criteria:\n\n* Unstable cardiovascular disease in the last 6 months\n* Psychiatric disorders or conditions that would preclude participation in the study intervention (e.g. untreated major depression or psychosis, untreated substance use disorder, severe personality disorder)\n* Pregnant\n* Currently participating in physical or occupational therapy\n* Presence of medical conditions or medications that would prohibit participation in an exercise program\n* Meeting exercise guidelines of 150 minutes of moderate intensity\u002F75 minutes of vigorous intensity physical activity per week plus consistent strength training (at least once per week) over the past 3 months. Assessed via Godin Leisure Time Questionnaire by study staff.\n* Adults unable to consent","15 Years","39 Years",{"count":501,"type":21},40,[55],"This study will evaluate strategies to improve physical function and promote exercise and physical activity in adolescents and young adults (AYAs) with sarcoma. The study will assess the feasibility of a standardized triage system for referring AYAs with sarcoma to appropriate exercise and rehabilitation services, and will also examine changes in physical function and health-related quality of life before and after a 12-week personalized exercise program.",[29,505,506],"Bone Sarcoma","Soft Tissue Sarcoma (STS)",[32,508,509],"bone sarcoma","soft tissue sarcoma","2026-06-16",{"date":419,"type":37},{"date":513,"type":21},"2026-08-01",{"date":515,"type":21},"2027-02-01",{"name":210,"class":44},3,{"id":519,"slug":4,"hasResults":11,"nctId":520,"briefTitle":521,"officialTitle":521,"acronym":522,"eligibilityCriteria":523,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":524,"targetDuration":4,"studyType":22,"phases":526,"briefSummary":527,"conditions":528,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":45},"100524050","NCT06103669","Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)","VALOROUS","Inclusion Criteria:\n\n1. Must have one of the following histologically and\u002For biochemically confirmed genitourinary malignancies:\n\n   1. Cohort A: Breast Malignancy\n   2. Cohort B: Gynecological Malignancy\n   3. Cohort C: Head and Neck Malignancies\n   4. Cohort D: Sarcomas\n   5. Cohort E: Other solid malignancy specified in the protocol\n2. Provision of signed and dated informed consent form.\n3. Stated willingness to comply with all study procedures and availability for the duration of the study.\n4. Age ≥18 years at time of consent.\n5. Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.\n6. ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. \\[Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment\\]\n7. ≤ 5 progressing or new metastatic lesions.\n8. All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and\u002F interventional radiologist.\n\nExclusion Criteria:\n\n1. Medical comorbidities precluding locally ablative therapies.\n2. History of treatment related toxicities that limit or prohibit application of locally ablative therapies.\n3. Progressing intracranial lesions.",{"count":525,"type":21},250,[55],"This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.",[61,529,71,29,530],"Oligoprogressive","Other Cancer","2026-06-11",{"date":533,"type":37},"2026-06-15",{"date":535,"type":37},"2023-10-05",{"date":537,"type":21},"2033-12",{"name":539,"class":44},"University of California, Davis",{"id":541,"slug":4,"hasResults":11,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":545,"eligibilityCriteria":546,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":547,"targetDuration":4,"studyType":22,"phases":549,"briefSummary":550,"conditions":551,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":269},"100576736","NCT06789172","A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors","A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors","INVOKE","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed disease, locally advanced or metastatic:\n\n   For Phase 1a:\n\n   Solid tumor with a COX2-associated immunosuppressive pathway, for which standard treatment options are not available, no longer effective, refused or not tolerated.\n\n   For Phase 1b:\n\n   For all cohorts, in the opinion of the investigator, all appropriate authorized treatment options should be exhausted\n   * Cohort 1: Sarcoma (fibrous sarcoma \\[myxofibrosarcoma or solitary fibrous tumor\\], dedifferentiated liposarcoma, undifferentiated pleomorphic sarcoma or pleomorphic sarcoma, or leiomyosarcoma), that is either refractory to or progressing on standard of care, with no more than 3 prior lines of systemic therapy. Patients with a solitary fibrous tumor can be included in the study without prior treatment if, in the investigator's opinion, it is in the participant's best interest and no established standard of care exists or is available.\n   * Cohort 2: NSCLC (squamous or adenomatous without EGFR\u002FALK mutations), with disease progression on a PD-(L)1 CPI regimen, and no more than 3 prior lines of systemic therapy. When known, PD-L1 status should be provided.\n   * Cohort 3: CRC (Microsatellite stable or Microsatellite instability - low), and no more than 4 prior lines of systemic therapy.\n   * Cohort 4: GC (gastric and gastro-esophageal junction adenocarcinoma), HER2-negative, planned to or currently receiving CPI monotherapy as maintenance of a first-line CPI + chemotherapy regimen, after chemotherapy cessation.\n2. ECOG performance status of 0 or 1.\n3. Recovery from any medically relevant AE\u002FirAE from previous treatment regimen (defined as recovery to Grade ≤1 level per CTCAE v 5.0 before Screening, or chronic, stable, Grade 2 AEs \\[not worsened to Grade \\>2 for \\>3 months prior to screening\\]).\n4. One or more new or growing tumor lesions amenable to a safe biopsy (at baseline, a suitable archival specimen obtained when not undergoing treatment and within 1 year \\[Phase 1a\\], or within 90 days and after the last administration of the previous systemic therapy \\[Phase 1b\\] is suitable). In addition (where applicable) an archival tumor biopsy collected before the start of the first-line treatment in the metastatic setting is requested (but optional).\n5. At least one target lesion measurable by RECIST 1.1 as noted by local investigators\u002Fradiologists.\n6. The ability to swallow and retain OKN4395 as an oral medication without significant gastrointestinal abnormalities that might alter absorption.\n7. The willingness and ability to comply with the evaluation, randomizations and requirements of the protocol. For Substudy 1, the ability to comply with the evaluation requirements includes the absence of any condition known to affect upper gastrointestinal motility, absorption, and pH.\n8. Adequate hematologic, renal, and hepatic function (based on local laboratory assessments):\n\n   1. Hematological variables: absolute neutrophil counts ≥1.5 × 109 \u002FL, platelet counts ≥75 × 109 \u002FL, and hemoglobin ≥8 g\u002FdL\n   2. Renal variables: creatinine clearance ≥ 60 mL\u002Fmin1 by Du Bois \\& Du Bois formula\n   3. Hepatic variables: total serum bilirubin ≤1.5 × ULN, AST and ALT ≤3 × ULN, and ALP ≤2.5 × ULN; except for hyperbilirubinemia of Gilbert's syndrome (participants with Gilbert's syndrome can be included if total serum bilirubin ≤5× ULN and direct bilirubin ≤1.5 x ULN)\n   4. Serum albumin ≥30 g\u002FL\n\nExclusion Criteria:\n\n1. Except for the current regimen in Cohort 4, ongoing or recent anticancer therapy within the following timeframe prior to first dose of study drug:\n\n   1. Chemotherapy, ADCs, or other antibodies \\\u003C 21 days\n   2. Immunotherapy or cellular therapy \\\u003C 28 days\n   3. Radiation therapy (palliative radiation for bone pain \\\u003C48 hours; stereotactic or small field brain irradiation \\\u003C7 days; all other radiation therapy \\\u003C14 days)\n   4. TKI or any other anticancer therapy \\\u003C 5 half-lives or \\\u003C 7 days, whichever is longer\n2. Central nervous system metastasis (radiologically progressive, or clinically symptomatic, or requiring immunosuppressive therapies \\[including low dose steroids\\]).\n3. Any active infection (bacterial, viral, fungal) requiring IV systemic therapy.\n4. Unstable COPD defined as frequent or severe exacerbations per investigator discretion.\n5. Known history of or active HBV (HBsAg reactive and\u002For HBV DNA detected) or HCV (HCV RNA detected) infection.\n6. HIV infection with CD4 lymphocyte count \\\u003C350 cells\u002FμL at time of Screening, or failure to achieve and maintain virologic suppression defined as confirmed HIV RNA level \\\u003C 50 or lower limit of detection by the local available assay at time of Screening and for at least 12 weeks prior to Screening.\n7. Known history of bleeding disorders, INR ≥1.5 × ULN at screening (or INR and\u002For aPTT within therapeutic range if on anticoagulation therapy), or a history of gastrointestinal bleeding (inflammatory, ulcerative, or diverticular) within the last 2 years.\n8. Known H. pylori infection without proof of eradication at least 2 months prior to screening.\n9. Systemic treatment with any drug known to impact gastrointestinal pH within 7 days (PPIs) or 12 hours (H2 antagonists) of first dose of OKN4395 (unless adapted after Substudy 1). Where said treatments have been used for more than 2 weeks prior to discontinuation, discontinuation should occur at least 21 days before first dose of OKN4395.\n10. Acute treatment with any systemic steroid therapy (\\>10 mg prednisone equivalent), or any corticosteroid medication within 14 days of first dose of OKN4395 for any condition.\n11. For participants planned to receive combination therapy: Ongoing and history of active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Any replacement therapy (i.e. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed. Participants with hyperthyroidism or hypothyroidism but that are stable on hormone replacement are also allowed.\n12. Systemic treatment with NSAIDs, COX2 inhibitors, or synthetic prostaglandins within 5 half-lives prior to the first dose of OKN4395 (acetylsalicylic acid ≤ 160 mg\u002Fday, or 325 mg ≤ 3 times\u002Fweek is permitted).\n13. Systemic treatment with strong inhibitors\u002Finducers of CYP and UGT enzymes within 14 days of first dose of OKN4395.\n14. QTcF interval of \\> 450 ms based on mean of the central triplicate readings.\n15. Known hypersensitivity to any excipients of the OKN4395 formulation or pembrolizumab (for combination cohorts).\n16. Pregnant or lactating women. Women of childbearing potential must have a negative serum pregnancy test at screening and have a negative a urine dipstick pregnancy test prior to the initiation of study treatment (can be done on C1-D1 visit).\n17. Evidence of any other active malignancy requiring systemic therapy within the 2 years prior to Screening. (Exceptions: non-melanoma skin cancer, in situ melanoma, in situ cervical cancer, ductal carcinoma in situ of the breast, or localized and presumed cured prostate cancer; participants on long-term anti-hormonal therapy for a prior malignancy are allowed if the malignancy has not been active within the prior 2 years).\n18. History or current evidence of any condition, surgical or medical therapy, or laboratory abnormalities that might confound the results of the study, make study drug administration hazardous, interfere with the participant's involvement for the full duration of the study, or make it difficult to monitor AEs such that, in the opinion of the treating physician, it is not in the best interest of the participant to participate",{"count":548,"type":21},146,[247],"The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab.\n\nThe overall objectives of this study are to determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of OKN4395 alone and in combination with pembrolizumab, OKN4395 and metabolites (broken-down substances) of OKN4395 levels in the blood, and antitumor activity of OKN4395 alone and in combination with pembrolizumab.\n\nThis study will be split into 2 parts. Part 1a will look at multiple doses of OKN4395 either alone (monotherapy) or with pembrolizumab (combination therapy) administered on day 1 of each 21-day cycle in patients with solid tumors until the participant has disease progression or discontinues for any reason. The dose of OKN4395 will be increased, after each group of 3 or more participants completes their first 3 weeks of treatment and their data is evaluated for safety, with a planned dose range from 10 mg twice a day to 450 mg twice a day through 13 dose levels. Part 1a also includes a parallel substudy (Substudy 1) consisting of at least 12 participants, aiming to test the effect of food and stomach acid on the levels of OKN4395 in the blood as well as its tolerability.\n\nPart 1b will evaluate OKN4395 alone and in combination with pembrolizumab administered on day 1 of each 21-day cycle in patients with selected cancer types. Part 1b will comprise 4 cohorts: Cohort 1 in sarcoma (OKN4395 alone), Cohort 2 in non-small cell lung cancer (NSCLC), Cohort 3 in colorectal cancer, and Cohort 4 in gastric cancer (GC), with cohorts 2 to 4 in combination with pembrolizumab.\n\nThe overall study will enrol approximately 146 participants with up to 54 participants to receive OKN4395 alone and 12 participants to receive OKN4395 in combination with pembrolizumab in Part 1a, and 80 participants in Part 1b split: 20 on monotherapy and 60 on combination therapy.\n\nThe study will be conducted in the US, Australia, UK and in the EU.",[552,29,553,554,251,555,556,557,558,559,560,561,562,563,564],"Solid Tumours","HNSCC","Non Small Cell Lung Cancer","Colorectal Cancer (CRC)","Myxofibrosarcoma (MFS)","Solitary Fibrous Tumors","Dedifferentiated Liposarcoma","Undifferentiated Pleomorphic Sarcoma (UPS)","Leiomyosarcoma","Leiomyosarcoma (LMS)","Gastric Cancer (GC)","Gastric Cancer Adenocarcinoma Metastatic","Gastric \u002F Gastroesophageal Junction Adenocarcinoma","2026-06-09",{"date":531,"type":37},{"date":568,"type":37},"2025-01-23",{"date":570,"type":21},"2028-09",{"name":572,"class":268},"Epkin",{"id":574,"slug":4,"hasResults":11,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":4,"eligibilityCriteria":578,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":579,"targetDuration":4,"studyType":22,"phases":581,"briefSummary":582,"conditions":583,"keywords":585,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":596,"locationsCount":598},"100517752","NCT06021626","A Study of CRD3874-SI in People With Solid Tumors","A Phase I Trial of CRD3874-SI, a STING Agonist, in Patients With Advanced\u002FMetastatic Malignant Solid Tumors","Inclusion Criteria:\n\n* Male or female age ≥ 18 years at the time of informed consent.\n* Be capable, willing, and able to provide written informed consent.\n* Be willing to comply with clinical trial instructions and requirements, including tumor biopsies (if feasible and required per protocol).\n* Patients must have a locally advanced or metastatic cancer, a malignant solid tumor that has progressed on at least one line of systemic therapy or for which no standard treatment is available, the participant is intolerant to available treatment, or the participant declined standard of care systemic therapy.\n* In the dose escalation phase study patients with the following tumor types will be eligible: Of note patients who declined or were intolerable of standard of care systemic therapy will be considered in all dose expansion cohorts.\n* Head and neck squamous cell carcinoma (HNSCC)\n* Participants must have histologically or cytologically confirmed recurrent and\u002For metastatic HNSCC and must have received 1-2 prior lines of systemic anti-cancer therapy including a checkpoint inhibitor (patients treated initially with immune checkpoint blockade alone followed by the addition of other drugs in combination \\[i.e., cytotoxic chemotherapy or EGFR inhibitor\\], will be considered 1 line of therapy.\n* HPV positive (p16 IHC positive or HPV RNA ISH positive), PD-L1 CPS score high (≥1)\n* HPV negative (p16 IHC negative or HPV RNA ISH negative), PD-L1 CPS score high (≥1)\n* Adenoid cystic carcinoma (ACC)\n* Participants must have histologically or cytologically confirmed recurrent and\u002For metastatic ACC (cancers arising from non-salivery gland primary sites are eligible) and may have received none or up 2 prior lines of systemic anti-cancer therapy.\n* Merkel cell carcinoma (MCC)\n* Participants must have histologically or cytologically confirmed recurrent and or metastatic MCC and must have received at least one but no more than 3 prior lines of systemic anti-cancer therapy including a checkpoint inhibitor and may not have received prior chemotherapy for MCC.\n* Monotherapy alone\n* Radiation therapy\n* Patients will receive palliative radiation therapy to a tumor site if they have at least one other site of measureable disease that can be chosen as the target lesion to assess response to investigational therapy.\n* Sarcoma that has demonstrated clinical benefit or an objective response to immune checkpoint blockade or sarcoma subtypes that are considered immunogenic subtypes including but not limited to undifferentiated pleomorphic (UPS) or myxofibrosarcoma (MFS), angiosarcoma, alveolara soft part sarcoma, or undifferentiated sarcoma will be considered.\n* Melanoma\n* Uveal Melanoma\n* Participants must have histologically or cytologically confirmed recurrent and\u002For metastatic uveal melanoma and received at least one but no more than two prior lines of systemic anti-cancer therapy including tebentafusp (if HLA-A 02:01+, unless patient declined or was deemed ineligible) and\u002For immune checkpoint inhibitor. Melphalan PHP will count as a line of therapy if give on its own. Unlimited partial hepatic directed therapy will be permitted.\n* Mucosal and Acral melanoma\n* Participants must have histologically or cytologically confirmed recurrent and\u002For metastatic mucosal or acral melanoma and received at least one but no more than two prior lines of systemic anti-cancer therapy including prior exposure to immune checkpoint inhibition. Patients treated with BRAF-MEK therapy may have up to 3 prior lines of therapy.\n* Non small cell lung cancer\n* Participants must have histologically or cytologically confirmed locally advanced\u002Fmetastatic non-small cell lung cancer with prior exposure to immune checkpoint inhibition and received at least one but no more than 2 prior lines of systemic anti-cancer therapy.\n* Participants must have histologically or cytologically confirmed locally advanced\u002Fmetastatic sarcoma and must have received at least one but no more than 2 prior lines of systemic anti-cancer therapy. Patients will receive palliative radiation therapy to a tumor site if they have at least one other site of measureable disease that can be chosen as the target lesion to assess response to investigational therapy\n* Adequate performance status: ECOG 0 or 1\u002FKPS 100-70%.\n* Life expectancy of at least three months after the first CRD3874 infusion, according to the Investigator's opinion\n* Presence of measurable disease per RECIST v1.1.Target lesion(s) must not be chosen from a previously irradiated field unless there has been radiographically and\u002For pathologically documented tumor progression in that lesion prior to enrollment.\n* In the dose expansion phase , participants must agree to have a pretreatment tumor biopsy for research purposes. Participants in whom biopsy is technically not feasible or in whom the associated procedure would result in unacceptable risk, in the opinion of the Investigator, or patients who do not wish to have a biopsy, archival tissue (most recently procured sample where tissue is available) may be used instead, if available.\n* In the dose expansion phase , participants must agree to on-treatment tumor biopsy for research purposes. Participants in whom biopsy is technically not feasible or in whom would result in unacceptable risk, in the opinion of the Investigator, or patients who do not wish to have a biopsy- may be exempted from the biopsy requirement with discussion with the Principal Investigator .\n* Female subject of childbearing potential (defined as a sexually mature female who has not undergone a hysterectomy or bilateral oophorectomy or who has not been naturally postmenopausal for at least 24 consecutive months) should have a negative serum pregnancy testing at screening visit and within 72 hours prior to the first dose of study medication.\n* Adequate organ function determined within 14 days of treatment initiation, defined as follows:\n\n  * Hemoglobin ≥ 9.0 g\u002FdL\n  * Absolute neutrophil count ≥ 1,000\u002Fmm\\^3 (1.0 x 10\\^9\u002FL)\n  * Platelet count ≥ 100,000\u002Fmm3 (100 x 10\\^9 \u002FL)\n  * Serum bilirubin ≤ 1.2x upper limit of normal (ULN) OR direct bilirubin ≤ ULN for participants with total bilirubin level \\> 1.2x ULN\n  * Aspartate aminotransferase (AST) ≤ 2.5x ULN OR ≤ 5x ULN for participants with liver metastases\n  * Alanine aminotransferase (ALT) ≤ 2.5x ULN OR ≤ 5x ULN for participants with liver metastases\n  * Albumin ≥ 2.5mg\u002FdL.\n  * Calculated creatinine clearance (CrCl) ≥ 50 mL\u002Fmin by Cockcroft-Gault formula or CKD-EPI 2021\n  * International Normalized Ratio (INR) or prothrombin time (PT) ≤1.5x ULN unless participant is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants.\n  * Activated partial thromboplastin time (aPTT) ≤ 1.5x ULN unless participant is receiving anticoagulant therapy as long as PT and PTT is within therapeutic range of intended use of anticoagulants\n  * Left ventricular ejection fraction (LVEF) \\> 50%, as measured by echocardiogram (2D-ECHO) or multi-gated acquisition scan (MUGA)\n\nExclusion Criteria:\n\n* Known prior severe hypersensitivity to an investigational product or any component of the study drug therapy's formulations including polyethylene glycol (PEG), (NCI CTCAE v5.0 Grade ≥ 3)\n* Evidence of clinically significant immunosuppression such as the following:\n\n  * Primary immunodeficiency state such as Severe Combined Immunodeficiency Disease\n  * Concurrent opportunistic infection\n  * Receiving systemic immunosuppressive therapy (\\> 2 weeks) including oral steroid doses \\> 10 mg\u002Fday of prednisone or equivalent within 7 days prior to enrollment. In the setting of non-immune mediated indications for use, chronic\u002Factive low dose steroid (equivalent to \\\u003C\u002F=10mg\u002Fday prednisone) use may be permitted at the discretion of the principal investigator.\n  * Current use of immunosuppressive medication, EXCEPT for the following:\n\nI. Intranasal, inhaled, ocular, topical steroids, or local steroid injection (e.g., intraarticular injection) II. Systemic corticosteroids at physiologic doses ≤ 10 mg\u002Fday of prednisone or equivalent III. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)\n\n* Prior organ transplantation, including allogenic stem-cell transplantation. Consideration will be given to allow patients with a history of autologous transplantation enroll if they are at least 5 years beyond the completion of the transplant pending discussion with the principal investigator.\n* History or evidence of symptomatic autoimmune disease (e.g., pneumonitis, glomerulonephritis, vasculitis, or other), or history of active autoimmune disease that has required systemic treatment (i.e., use of corticosteroids, immunosuppressive drugs or biological agents used for treatment of autoimmune diseases) in past 2 years prior to enrollment. Replacement therapy (e.g., thyroxine for hypothyroidism, insulin for diabetes or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment for autoimmune disease.\n* Systemic antibiotics received ≥ 7 days prior to the first dose of study drugs.\n* Uncontrolled medical condition including current active infection requiring systemic therapy or symptomatic congestive heart failure within 6 months that in the investigators opinion compromise the ability of the patient to complete all study related requirements safely\n* Inability to comply with protocol required procedures\n* Resting QTc interval by Friderica's formula ≥ 470 ms on a 12-lead electrocardiogram (ECG) for males and females\n* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment or 5 half-lives, if shorter.\n* Has had prior chemotherapy or targeted small molecule therapy within 3 weeks, anti-cancer monoclonal antibody (mAb) within 4 weeks or OR 5 half-lives, if shorter, or radiation therapy within 2 weeks prior to the first CRD3874 infusion prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent\n\n  * Note: Alopecia or other Grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable\n  * Note: If patient received major surgery, they must have recovered adequately from the toxicity and\u002For complications from the intervention prior to starting study therapy\n* Evidence of clinically significant interstitial lung disease, history of interstitial lung disease, or active, noninfectious pneumonitis related to prior immunotherapy treatment.\n* History of unstable or deteriorating cardiovascular disease within the previous 6 months prior to screening including but not limited to the following:\n\n  * Unstable angina or myocardial infarction\n  * CVA\u002Fstroke\n  * Congestive heart failure (New York Heart Association \\[NYHA\\] Class III or IV\n  * Uncontrolled clinically significant arrhythmias.\n* Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis.\n* Patients with previously treated brain metastases or carcinomatous meningitis may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment.\n* Has received a live vaccine within 30 days of the planned start of study drug. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.\n* Patients known to be positive for active Hepatitis B (HBsAg reactive with detectable HBV DNA), or Hepatitis C (HCV RNA (qualitative) is detected)\n\n  1. Patients with chronic hepatitis B (positive HBsAg and\u002For HBcAb and negative HBV DNA by PCR) are eligible for this study if they are on suppressive anti-viral therapy and deemed safe by a gastroenterologist\n  2. Patient who is HCV Ab positive but HCV RNA negative due to prior treatment or natural resolution will be considered eligible.\n* Known history of human immunodeficiency virus (HIV) (HIV 1\u002F2 antibodies) disease that is not controlled. Note HIV-positive patients will be considered eligible if:\n\n  * Established ART for at least four weeks and have an HIV viral load less than 400 copies\u002FmL prior to enrollment\n  * CD4+ T-cell (CD4+) counts ≥ 350 cells\u002FuL\n  * No opportunistic infection within the past 12 months\n  * Has a known history of active TB (Bacillus Tuberculosis)\n* Women who are pregnant or breastfeeding\n* Patients expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through three months after the last dose of study treatment(s).\n* Female participants of childbearing potential and male participants who are unwilling to use acceptable method(s) of effective contraception during study treatment and until six months for female and three months for males after the last dose of CRD3874-SI. Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the participant.\n\n(Note: Women not of childbearing potential are defined as: Any female who is postmenopausal \\[age \\> 55 years with cessation of menses for 12 or more months or less than 55 years but with no spontaneous menses for at least two years or less than 55 years and spontaneous menses within the past one year but currently amenorrheic (e.g., spontaneous or secondary to hysterectomy) and with postmenopausal gonadotropin levels (luteinizing hormone and follicle-stimulating hormone levels \\> 40 IU\u002FL) or postmenopausal estradiol levels (\\\u003C 5 ng\u002FdL) or according to the definition of \"postmenopausal range\" for the laboratory involved\\] or who have had a hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.)\n\n* The presence of a concurrent active malignancy that in the opinion of the investigator could compromise the conduct of the study or interfere with determining the outcomes of the study objectives.\n* History of non-infectious colitis.",{"count":580,"type":21},81,[247],"This study will test the safety of a study drug called CRD3874-SI. The researchers will test different doses of CRD3874-SI to find the highest dose that causes few or mild side effects in participants. After the researchers find the highest safe dose of CRD3874-SI, they will test that dose in new groups of participants to help them learn more about the side effects of the study drug and find out whether CRD3874-SI is an effective treatment for for patients with advanced or metastatic malignant solid tumors including sarcoma and Merkel Cell Carcinoma. (MCC), Head and neck squamous cell carcinoma (HNSCC), Adenoid cycstic carcinoma (ACC), Uveal Melanoma, Muscosal and Acral melanoma, and Non small cell lung cancer. The researchers will also look at how the body absorbs, distributes, and gets rid of CRD3874-SI, and the how the body and immune system respond to CRD3874-SI.",[29,584],"Merkel Cell Carcinoma",[586,587,588],"CRD3874-SI","23-169","Advanced\u002FMetastatic Malignant Solid Tumors","2026-06-04",{"date":591,"type":37},"2026-06-05",{"date":593,"type":37},"2023-08-25",{"date":595,"type":21},"2029-08",{"name":597,"class":44},"Memorial Sloan Kettering Cancer Center",7,{"id":600,"slug":4,"hasResults":11,"nctId":601,"briefTitle":602,"officialTitle":603,"acronym":4,"eligibilityCriteria":604,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":605,"enrollmentInfo":606,"targetDuration":4,"studyType":22,"phases":608,"briefSummary":609,"conditions":610,"keywords":613,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":634},"100570708","NCT06710756","Lead-212 PSV359 Therapy for Patients With Solid Tumors","A Phase I\u002FIIa Image-Guided, Alpha-Particle Therapy Study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in Patients With Solid Tumors That Are Known to be Fibroblast Activation Protein (FAP)-Positive","Inclusion Criteria:\n\n* Aged ≥ 18 years\n* Satisfactory organ function as determined by laboratory testing\n* Eastern Cooperative Oncology Group performance (ECOG) status of 0 to 1\n* Life expectancy \\> 3 months\n* Progressive disease despite standard therapy or for whom no standard therapy exists\n* Positive \\[203Pb\\]Pb-PSV359 SPECT\u002FCT scan showing uptake of \\[203Pb\\]Pb-PSV359 in at least 1 known lesion on the 1-hour SPECT\u002F CT scan\n* Histological, pathological, and\u002For cytological confirmation of solid tumor malignancy that is locally advanced or metastatic\n\nExclusion Criteria:\n\n* Known hypersensitivity to the active agent or any of the excipients\n* Active secondary malignancy\n* Pregnancy or breastfeeding a child\n* Known brain metastases\n* Known active or uncontrolled infections requiring ongoing antifungals or antibiotics in the 3 days prior to enrollment\n* Known medical condition which would make this protocol unreasonably hazardous for the patient\n* Existence of any medical or social issues likely to interfere with study conductor that may cause increased risk to the subject or to others, e.g., lack of ability to follow radiation safety precautions\n* Medical history of a condition resulting in a severe allergic reaction such as anaphylaxis or angioedema to known components of the investigational product or excipients\n* Major surgery within 21 days prior to the administration of \\[212Pb\\]Pb-PSV359; the subject must be sufficiently recovered and stable before treatment administration\n* Diagnosis of deep vein thrombosis or pulmonary embolism within 4 weeks prior to enrollment into the study\n* Current abuse of alcohol or illicit drugs\n* Treatment with any live\u002Fattenuated vaccine in the 7 days prior to enrollment\n* Previous treatment with any systemic anticancer therapy within 4 weeks prior to treatment on study","90 Years",{"count":607,"type":21},112,[247,24],"Phase I\u002FIIa image-guided, alpha-particle therapy study of \\[203Pb\\]Pb-PSV359 and \\[212Pb\\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.",[611,67,65,612,72,71,29,370],"Pancreatic Ductal Adenocarcinoma","Colorectal Cancer",[614,615,616,378,617,618,619,620,621,622,623,624,625],"Fibroblast Activation Protein","Solid tumor malignancy","Gastric cancer","Colorectal cancer","Ovarian cancer","Head and neck cancer","Theronostic","Radiopharmaceutical","Radiotherapy","Alpha Particle","Pb-203","Pb-212","2026-06-03",{"date":591,"type":37},{"date":629,"type":37},"2025-04-28",{"date":631,"type":21},"2032-05-28",{"name":633,"class":268},"Perspective Therapeutics",8,{"id":636,"slug":4,"hasResults":11,"nctId":637,"briefTitle":638,"officialTitle":639,"acronym":640,"eligibilityCriteria":641,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":642,"targetDuration":4,"studyType":22,"phases":643,"briefSummary":644,"conditions":645,"keywords":646,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":651,"startDateStruct":652,"completionDateStruct":653,"leadSponsor":655,"locationsCount":237},"100552716","NCT06476704","Study of Preoperative RAdiation Therapy With Concomitant Liposomal Transcrocetin (L-TC) in Soft tISsue Sarcomas","Phase 2 Study of Preoperative RAdiation Therapy With Concomitant Liposomal Transcrocetin (L-TC) in Soft tISsue Sarcomas","PRACTISS","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Localized or locally advanced soft tissue sarcoma of extremity proven by biopsy histological grade 2 and 3.\n* Pathological expert proof-reading in reference centers\n* HFRT and surgery planned (regardless the potential inclusion in this trial) as decided in a multidisciplinary tumor board, in reference centre (European Society for Medical Oncology (ESMO) guideline 2021)\n* R0 surgery is feasible, in reference centers\n* Pre-biopsy MRI available\n* Performance status of 0-2 and life expectancy of at least 6 months\n\nExclusion Criteria:\n\n* Patient who cannot undergo MRI\n* Patients with localized or locally advanced soft tissue sarcoma of extremity proven by biopsy with histological grade 1\n* Previous radiation in the area\n* Woman who is pregnant or breastfeeding\n* Soft tissue sarcoma developed in irradiated area.\n* Patients with myxoid liposarcoma, embryonal or alveolar rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, angiosarcoma, primitive neuroectodermal tumor, desmoid-type fibromatosis, or dermatofibrosarcoma protuberans\n* Patient with metastatic disease, other concomitant cancer or history of cancer treated and controlled within the previous 3 years.",{"count":395,"type":21},[24],"This is phase II randomized, multicenter study of treatment with L-TC and preoperative HFRT in patients who were aged 18 years or older with documented localised or locally advanced soft-tissue sarcoma of the extremity.\n\nEligible patients will be randomly assigned 2:1 to receive a preoperative HFRT alone (Arm A) or L-TC with preoperative HFRT (Arm B).",[29],[647,509,648,649,650],"hypofractionated radiotherapy","hypoxia","liposomal transcrocetin","neo-adjuvant",{"date":589,"type":37},{"date":77,"type":21},{"date":654,"type":21},"2033-06-01",{"name":656,"class":44},"Centre Paul Strauss",{"id":658,"slug":4,"hasResults":11,"nctId":659,"briefTitle":660,"officialTitle":661,"acronym":4,"eligibilityCriteria":662,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":663,"targetDuration":4,"studyType":22,"phases":664,"briefSummary":665,"conditions":666,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":667,"lastUpdatePostDateStruct":668,"startDateStruct":669,"completionDateStruct":671,"leadSponsor":673,"locationsCount":45},"100594030","NCT07014137","A Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas","A Phase II Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas","Inclusion Criteria:\n\n1. Be willing and able to provide written informed consent\u002Fassent for the trial.\n2. Be \\>18 years of age on day of signing informed consent.\n3. Have one of the following advanced (unresectable and\u002For metastatic) solid tumor indications:\n\n   1. Intimal sarcoma\n   2. Head and neck angiosarcoma\n   3. Epithelioid hemangioendothelioma (EHE)\n4. Have measurable disease based on RECIST v1.1.\n5. Have a performance status of 0, 1, or 2 on the ECOG Performance Scale.\n6. Have the ability to swallow and retain orally administered medications.\n7. Demonstrate adequate organ function as defined in Table 1, all screening labs should be performed within 10 days of treatment initiation.\n8. Female subject of childbearing potential should have a negative serum pregnancy within 72 hours prior to receiving the first dose of study medication.\n9. Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication (Reference Section 7.1.4.3). Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \\> 1 year.\n10. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.\n\nExclusion Criteria:\n\nThe subject must be excluded from participating in the trial if the subject:\n\n1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.\n2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. Use of steroids at physiological dose is allowed (i.e. less than or equal to prednisone 10mg per day)\n3. Has had prior treatment with any anti-PD-1, anti-PD-L1 or other antibodies specifically targeting the immune checkpoint pathways.\n4. Has had a prior anti-cancer monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.\n5. Has active gastrointestinal condition that may affect the absorption of ABSK043, according to investigator.\n6. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.\n\n   * Note: Subjects with ≤ Grade 2 neuropathy or alopecia are an exception to this criterion and may qualify for the study.\n   * Note: If subject received major surgery, they must have recovered adequately from the toxicity and\u002For complications from the intervention prior to starting therapy.\n7. Has a known additional malignancy within the last 3 years or continues to receive antineoplastic treatment after curative intent surgery. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.\n8. Has known active central nervous system (CNS) metastases and\u002For leptomeningeal disease. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include leptomeningeal disease which is excluded regardless of clinical stability.\n9. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n10. Has known history of, or any evidence of active, non-infectious pneumonitis.\n11. Has evidence of interstitial lung disease.\n12. Has an active infection requiring systemic treatment.\n13. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n14. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n15. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.\n16. Has a known history of Human Immunodeficiency Virus (HIV) with detectable viral load.\n17. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected).\n18. A marked baseline prolongation of QT\u002FQTc interval (e.g., repeated demonstration of a QTc interval \\>450 milliseconds (ms)).\n19. A history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).\n20. The use of concomitant medications that prolong the QT\u002FQTc interval.",{"count":434,"type":21},[24],"ABSK043 is a new type of experimental drug that blocks a protein called programmed cell death ligand 1 (PD-L1), which is important in controlling the body's response to harmful substances including cancer cells. By blocking PD-L1 from working, ABSK043 may allow the body's immune system to recognize and kill cancer cells.\n\nABSK043 is considered \"experimental\" because it has not been approved for sale by Health Canada. Health Canada has approved the study drug to be administered in this research study.\n\nThe main purposes of this study are:\n\n* To see if patients with your type of cancer benefit from ABSK043.\n* To evaluate the safety and tolerability of ABSK043.\n* To identify biomarkers (Biological flags used to measure disease progress or drug effect.) in tumor tissues or blood that might help identify patients whose cancers respond to ABSK043, and which patients may develop side effects from these study drugs. Examples of biomarkers include the type of white blood cells in your tumor or proteins in your blood.\n\nIt is anticipated that about 20 people will take part in this study from the Princess Margaret Cancer Centre.",[29],"2026-06-02",{"date":589,"type":37},{"date":670,"type":37},"2025-09-09",{"date":672,"type":21},"2027-03-02",{"name":674,"class":44},"University Health Network, Toronto",{"id":676,"slug":4,"hasResults":11,"nctId":677,"briefTitle":678,"officialTitle":679,"acronym":680,"eligibilityCriteria":681,"healthyVolunteers":11,"sex":16,"minAge":498,"maxAge":682,"enrollmentInfo":683,"targetDuration":4,"studyType":22,"phases":684,"briefSummary":685,"conditions":686,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":689,"lastUpdatePostDateStruct":690,"startDateStruct":692,"completionDateStruct":694,"leadSponsor":696,"locationsCount":4},"100637923","NCT07614620","Effect of Hypnosis in the Management of Anxiety and Chemo-induced Symptoms in Adolescents and Young Adults With Sarcoma or Germ Cell Tumor and in Young Women With Breast Cancer","Effect of Hypnosis in the Management of Anxiety and Chemo-induced Symptoms in Adolescents and Young Adults With Sarcoma or Germ Cell Tumor and in Young Women With Breast Cancer.","HYPNO-AJA2","Inclusion Criteria:\n\n1. Newly diagnosed patients receiving initial care and follow-up at the Institut Bergonié during treatment:\n\n   1. Adolescents or young adults (AJA) aged 15 to 39 with soft tissue or bone sarcoma or a germ cell tumor (testicular, ovarian),\n   2. Young women aged 15 to 49 with breast cancer.\n2. Treatment with neoadjuvant chemotherapy based on anthracyclines and\u002For alkylating agents.\n3. Treatment administered as:\n\n   1. Inpatient for patients with soft tissue or bone sarcoma or a germ cell tumor (testicular, ovarian),\n   2. Outpatient or day hospital for female patients with breast cancer.\n4. Dated and signed informed consent (if the patient is a minor, consent must also be signed by the legal guardians).\n5. Patient enrolled in a social security program in accordance with current regulations.\n\nExclusion Criteria:\n\n1. Known contraindications to hypnosis (psychotic disorders, mental disorders, confusion, deafness, severe cognitive impairment, etc.)\n2. Patients who have already undergone hypnosis sessions within 6 months prior to enrollment.\n3. Geographic, social, or psychological factors rendering the patient unable to comply with the study's follow-up and procedures.\n4. Patients who are deprived of their liberty or subject to a legal protection measure (guardianship, conservatorship, judicial protection, or family authorization).","49 Years",{"count":245,"type":21},[55],"The HYPNO-AJA 2 study is a prospective single-center interventional clinical trial conducted at the Institut Bergonié to evaluate the effectiveness of hypnosis in reducing anxiety and chemotherapy-related symptoms in adolescents, young adults (AYAs), and young women undergoing cancer treatment. The study focuses on patients aged 15-39 with sarcoma or germ cell tumors and women aged 15-49 with breast cancer receiving neoadjuvant chemotherapy.\n\nCancer treatment in AYAs is frequently associated with high levels of psychological distress, particularly anxiety related to chemotherapy sessions, invasive procedures, and repeated hospitalizations. Previous studies suggest that hypnosis may help reduce anxiety, pain, nausea, and emotional distress in oncology patients, but evidence remains limited in AYA populations and specific cancer types such as sarcoma, germ cell tumors, and breast cancer. HYPNO-AJA 2 aims to address this gap by assessing the feasibility, safety, and therapeutic value of hypnosis during chemotherapy.\n\nThe study's primary objective is to determine whether hypnosis can significantly reduce anxiety symptoms during chemotherapy. Secondary objectives include evaluating its effects on nausea and vomiting, pain, medication consumption (anxiolytics and antiemetics), quality of life, body image perception, and patient satisfaction.\n\nThe trial will include 70 participants divided into two cohorts:\n\n* 35 hospitalized patients with sarcoma or germ cell tumors;\n* 35 outpatients with breast cancer treated in a day hospital setting.\n\nEligible participants must be newly diagnosed, treated at Institut Bergonié, and receiving chemotherapy based on anthracyclines and\u002For alkylating agents. Patients with contraindications to hypnosis, severe psychiatric or cognitive disorders, recent hypnosis exposure, or inability to comply with follow-up procedures are excluded.\n\nThe intervention consists of a hypnosis session performed during the second chemotherapy cycle by a specialized oncology nurse trained in Ericksonian hypnosis and pain management. Sessions will last between 30 and 60 minutes and take place in a private and comfortable environment. The hypnosis procedure includes a preparatory discussion, hypnotic induction, progressive return to normal consciousness, and debriefing adapted to the patient's needs.\n\nAnxiety levels will be assessed using a Visual Analog Scale (VAS-Anxiety) before and after chemotherapy cycles 1, 2, and 3. Cycle 2 includes hypnosis, whereas cycles 1 and 3 do not. The primary endpoint is the difference in anxiety levels after cycle 2 compared with cycle 3. Secondary outcomes will evaluate chemotherapy-induced nausea and vomiting using the PRO-CTCAE system, pain intensity, medication use, quality of life through the EORTC QLQ-C30 questionnaire, body image changes using the Body Image Scale, and satisfaction with hypnosis sessions.\n\nThe planned enrollment period is 18 months, with a total study duration of 24 months and individual patient participation lasting approximately six months. Statistical analyses will compare anxiety scores after chemotherapy with and without hypnosis using paired statistical tests. Based on preliminary results from the earlier HYPNO-AJA-1 pilot study, the sample size is expected to provide more than 90% statistical power to detect clinically meaningful reductions in anxiety.\n\nThe investigators expect hypnosis to improve patients' psychological well-being, reduce symptom burden and medication use, enhance quality of life and body image acceptance, and strengthen the therapeutic relationship between patients and caregivers. More broadly, the study may support the integration of hypnosis into supportive oncology care pathways as a low-cost, non-pharmacological intervention adapted to young cancer patients.",[29,687,688,61],"Germ Cell Tumor of Testis","Ovarian Tumor","2026-05-22",{"date":691,"type":37},"2026-05-29",{"date":693,"type":21},"2026-09-15",{"date":695,"type":21},"2028-12",{"name":697,"class":44},"Institut Bergonié",{"id":699,"slug":4,"hasResults":11,"nctId":700,"briefTitle":701,"officialTitle":702,"acronym":4,"eligibilityCriteria":703,"healthyVolunteers":11,"sex":16,"minAge":704,"maxAge":4,"enrollmentInfo":705,"targetDuration":4,"studyType":22,"phases":706,"briefSummary":707,"conditions":708,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":709,"lastUpdatePostDateStruct":710,"startDateStruct":711,"completionDateStruct":713,"leadSponsor":715,"locationsCount":45},"100524828","NCT06113809","Palbociclib and Pembrolizumab in Sarcoma","Phase Ib Trial Evaluating the Combination of CDK4 Inhibitor With Immunotherapy in Patients With Sarcoma","Inclusion Criteria\n\nA potential subject must meet all the following inclusion criteria to be eligible to participate in the study:\n\n* Male or female patients aged \\> or = 12 years old\n* ECOG Performance Status of \\\u003C or = 2\n* Any patient with the diagnosis of locally advanced, unresectable or metastatic sarcoma for which PD-1 inhibitors are approved (undifferentiated pleomorphic sarcoma, myxofibrosarcoma, angiosarcoma, pleomorphic rhabdomyosarcoma, pleomorphic liposarcoma, alveolar soft part sarcoma) who have progressed on at least 1 prior line of therapy. Prior immunotherapy treatment is allowed, including prior treatment with a PD-1 inhibitor.\n* Patients with no known CNS disease, except for treated brain metastasis. Treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment and no ongoing treatment for dexamethasone (as ascertained by clinical examination and brain imaging) during the screening period. Stable dose of anticonvulsants is allowed. Treatment for brain metastases may include whole brain radiotherapy, radiosurgery, or a combination as deemed appropriate by the treating physician. Patients with CNS metastases treated by neurosurgical resection or brain biopsy performed within 3 months prior to Day 1 will be excluded.\n* Ability to understand and the willingness to sign a written informed consent or assent in case of patients \\\u003C 18 years old.\n\nExclusion Criteria\n\nA potential subject who meets any of the following exclusion criteria is ineligible to participate in the study:\n\n* Lab values in the below ranges:\n* Neutrophil count \\\u003C 1000\u002Fmm3\n* Platelet count \\\u003C 100,000\u002Fmm3L\n* Hemoglobin \\\u003C 9 g\u002FdL (transfusion to meet eligibility allowed)\n* AST\u002FSGOT and ALT\u002FSGPT \\> 3.0x upper limit of normal (ULN) without disease involvement or \\> 5.0x ULN if the transaminase elevation is due to disease involvement\n* Alkaline phosphatase \\> 5.0x ULN without known bony metastases\n* Serum bilirubin \\> 1.5x ULN\n* Serum creatinine \\> 1.5x ULN or 24-hour creatinine clearance \\\u003C 30 mL\u002Fmin per Cockroft- Gault equation\n* Total serum calcium \\\u003C lower limit of normal (LLN) or if calcium is below LLN the corrected calcium for serum albumin is \\> LLN\n* Serum potassium \\\u003C 3.0\n* Serum sodium \\\u003C 130\n* Serum albumin \\\u003C 2.5 g\u002FdL\n* History of myocardial infarction. unstable angina, stroke or transient ischemic attack within 6 months prior to Day 1\n* History or drug induced pneumonitis (both pembrolizumab and palbociclib can cause pneumonitis)\n* Subjects requiring hemodialysis\n* Patients with severe hepatic impairment (Childs-Pugh Class C).\n* Other concurrent severe and\u002For uncontrolled medical conditions in the opinion of the investigator which will preclude participation\n* Pregnancy (positive pregnancy test) or lactation\n* Concomitant use of any other anti-cancer therapy or radiation therapy of the target lesion. Palliative radiation therapy is permitted to non-target lesions.\n* Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent","12 Years",{"count":634,"type":21},[247],"This is a single-arm open-label window of opportunity clinical study assessing the impact of pre-treatment with palbociclib in patients with soft tissue sarcomas for which PD-1 inhibitors are approved (includes undifferentiated pleomorphic sarcoma, myxofibrosarcoma, angiosarcoma, pleomorphic rhabdomyosarcoma, pleomorphic liposarcoma, or alveolar soft part sarcoma).",[29],"2026-05-20",{"date":689,"type":37},{"date":712,"type":37},"2024-02-01",{"date":714,"type":21},"2028-07",{"name":716,"class":44},"John Rieth",{"id":718,"slug":4,"hasResults":11,"nctId":719,"briefTitle":720,"officialTitle":720,"acronym":721,"eligibilityCriteria":722,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":723,"targetDuration":4,"studyType":22,"phases":725,"briefSummary":726,"conditions":727,"keywords":729,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":709,"lastUpdatePostDateStruct":730,"startDateStruct":731,"completionDateStruct":733,"leadSponsor":735,"locationsCount":45},"100456579","NCT05225428","Video Education With Result Dependent dIsclosure","VERDI","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Current or prior diagnosis of breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, colorectal cancer, renal cancer, melanoma, or sarcoma\n* Ability to understand spoken or written English or Spanish in a healthcare context\n* Ability to understand and the willingness to sign a written informed consent document\n* Black or Latinx (qualitative assessment study only)\n\nExclusion Criteria:\n\n* Prior cancer genetic testing\n* Prior germline genetic testing\n* Active hematologic malignancy (e.g. chronic lymphocytic leukemia)\n* Currently pregnant\n* Currently incarcerated",{"count":724,"type":21},1020,[55],"The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more diverse patient population at risk for hereditary cancers.",[728,61,72,73,74,612,409,116,29],"Genetic Testing",[728,61,72,73,74,612,409,116,29],{"date":689,"type":37},{"date":732,"type":37},"2022-08-04",{"date":734,"type":21},"2026-10-01",{"name":210,"class":44},{"id":737,"slug":4,"hasResults":11,"nctId":738,"briefTitle":739,"officialTitle":740,"acronym":4,"eligibilityCriteria":741,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":742,"targetDuration":4,"studyType":22,"phases":744,"briefSummary":745,"conditions":746,"keywords":747,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":751,"lastUpdatePostDateStruct":752,"startDateStruct":753,"completionDateStruct":755,"leadSponsor":757,"locationsCount":4},"100640082","NCT07602777","A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)","Phase 1b\u002F2 Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Previously Treated Unresectable Advanced or Metastatic Sarcomas","Inclusion Criteria:\n\n\\- Participants are eligible to be included in the study only if all of the following criteria apply\n\n* Participants must be ≥ 12 years of age.\n* Has histologically confirmed unresectable advanced or metastatic R\u002FR OSA (Cohort 1) or unresectable advanced or metastatic STS (Cohort 2) that has progressed to at least one prior line of systemic therapy.\n* Has documented disease progression on the last line of systemic treatment as confirmed by radiological imaging\n* Has an ECOG performance status of 0 or 1, or Lansky PS\u002FKarnofsky PS ≥ 70% for adolescent participants, with no deterioration in the 2 weeks prior to first dose\u002Frandomization.\n* Has adequate organ function.\n* All participants, or their legal guardians, must provide signed informed consent and agree to follow the study protocol before starting any study activities\n\nExclusion Criteria:\n\n\\- Participants are excluded from the study if any of the following key exclusion criteria apply:\n\n* Has received any prior therapy with an Antibody-drug-conjugates (ADC) with a TOPO1-inhibitor payload.\n* Has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.\n* Has severe, uncontrolled or active cardiovascular disorders.\n* Known active infectious diseases requiring systemic treatment or known Human immunodeficiency virus (HIV).\n* Has symptomatic brain metastases or untreated progression exclusively due to brain metastasis during or after the last treatment prior to screening, evidence of leptomeningeal\u002Fmeningeal\u002Fbrainstem metastasis or evidence of spinal cord metastases.\n* Has received treatment with an investigational agent within 4 weeks of the first dose of study intervention.\n* Is pregnant or breastfeeding.",{"count":743,"type":21},113,[247,24],"The main goal of this study is to test a new medicine, Risvutatug Rezetecan also called Ris-Rez. We want to see if this medicine can help people with certain types of cancer, whether its safe to use, how well people tolerate it, and how their bodies handle the drug (how its absorbed and broken down). This research is for adolescents and adults who have either: Osteosarcoma, which is a type of bone cancer, or Soft Tissue Sarcoma, which is a type of cancer that starts in soft body tissues (like muscle, fat, or nerves). In both cancer types the cancer must have already been treated, but has come back or spread, and cant be removed by surgery",[29],[748,749,750,29],"EMBOLD Sarcoma-202","Risvutatug Rezetecan","Ris-Rez","2026-05-19",{"date":689,"type":37},{"date":754,"type":21},"2026-07-14",{"date":756,"type":21},"2029-12-17",{"name":758,"class":268},"GlaxoSmithKline",{"id":760,"slug":4,"hasResults":11,"nctId":761,"briefTitle":762,"officialTitle":762,"acronym":4,"eligibilityCriteria":763,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":764,"enrollmentInfo":765,"targetDuration":4,"studyType":22,"phases":767,"briefSummary":768,"conditions":769,"keywords":774,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":778,"lastUpdatePostDateStruct":779,"startDateStruct":780,"completionDateStruct":781,"leadSponsor":783,"locationsCount":45},"100554750","NCT06503146","18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection","* INCLUSION CRITERIA:\n* Histologically confirmed pancreatic ductal adenocarcinoma (PDAC), cholangiocarcinoma, hepatocellular carcinoma (HCC), gastric cancer, bladder cancer, ovarian cancer, pheochromocytoma\u002Fparaganglioma (PPGL), small cell lung cancer (SCLC) or extrapulmonary neuroendocrine cancer (EP-NEC), mesothelioma or sarcoma.\n* Participants must be scheduled or intended to receive treatment for their cancer.\n* Evaluable disease\n* \\>= 18 years old.\n* Eastern Cooperative Oncology Group (ECOG) performance score \\\u003C= 2.\n* Individuals of child-bearing potential (IOCBP) and individuals that can father children must agree to use effective contraception (barrier, hormonal, intrauterine device (IUD), surgical sterilization, abstinence) at the study entry and for 2 months after each (18F) FAPI-74 imaging. Sperm may not be frozen or donated within the same period.\n* Must be willing to discontinue breastfeeding for 2 months after each study imaging.\n* The ability of participant to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to \\[18F\\]FAPI-74 or other agents used in the study.\n* History of severe claustrophobia unresponsive to oral anxiolytics or history of any other condition preventing the ability to lie on the imaging scanner for up to 45 minutes.\n* Weight \\> 350 lbs., or inability to fit within the imaging gantry.\n* Positive Beta-human chorionic gonadotropin (Beta-HCG) serum or urine pregnancy test performed in IOCBP at screening.\n* Uncontrolled intercurrent illness, or medical condition(s) including but not limited to renal failure, liver failure, or psychiatric illness\u002Fsocial situations evaluated by medical history and physical exam that would limit compliance with study requirements and potentially increase risk for the participant.\n* Serum creatinine \\> 2 times the upper limit of normal.\n* Liver transaminases (ALT, AST) greater than 3 times the upper limit of normal.","120 Years",{"count":766,"type":21},320,[24],"Background:\n\nFibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. \\[18F\\]FAPI-74 is a new PET (positron emission tomography) tracer, a substance that is injected into a person s body before an imaging scan. Researchers believe that \\[18F\\]FAPI-74 PET imaging may be able to visualize cancer more effectively than the approved tracers. If so, the new tracer would make it easier to find FAP-positive tumors in the body.\n\nObjective:\n\nTo see if \\[18F\\]FAPI-74 PET scan is as good or better than other imaging methods for detecting certain cancers.\n\nEligibility:\n\nPeople aged 18 years or older with one of these cancer types: pancreatic ductal adenocarcinoma (PDAC), cholangiocarcinoma, hepatocellular carcinoma (HCC), gastric cancer, bladder cancer, ovarian cancer, pheochromocytoma\u002Fparaganglioma (PPGL), small cell lung cancer (SCLC) or extrapulmonary neuroendocrine cancer (EP-NEC), mesothelioma or sarcoma. Participants must be scheduled or intended to receive treatment for cancer.\n\nDesign:\n\nParticipants will have 2 baseline scans: an \\[18F\\]FAPI-74, and the approved tracer \\[18F\\]-FDG.\n\nThe \\[18F\\]FAPI-74 will be infused through a needle inserted into a vein. About 1 hour later, the participant will undergo imaging.\n\nWithin 1 week, participants will undergo the same scanning procedures with the approved tracer.\n\nIf the baseline scan with \\[18F\\]FAPI-74 shows the tumor(s), scans with this tracer will be repeated when their regular treatment regimen calls for scans again. If the scan with the regular FDG also show tumors, this scan will be repeated within the same week as the repeated \\[18F\\]FAPI-74 scan. If \\[18F\\]-FAPi PET scan shows no tumor(s), scans will not be repeated.\n\nIf the participant's cancer progresses within 2 years, scans may be repeated.\n\nFollow-up calls will continue for 2 years.",[29,770,370,771,611,72,772,67,773,313],"Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)","Pheochromocytoma\u002FParaganglioma (PPGL)","Hepatocellular Carcinoma","Cholangiocarcinoma",[775,776,777],"Fluorodeoxyglucose F18","PET Imaging","18F-Fibroblast Activation Protein Inhibitor","2026-05-16",{"date":751,"type":37},{"date":670,"type":37},{"date":782,"type":21},"2030-06-01",{"name":298,"class":299},""]